- Diabetes, obesity and metabolism
- Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE)
-
Nam Hoon Kim, Juneyoung Lee, Suk Chon, Jae Myung Yu, In-Kyung Jeong, Soo Lim, Won Jun Kim, Keeho Song, Ho Chan Cho, Hea Min Yu, Kyoung-Ah Kim, Sang Soo Kim, Soon Hee Lee, Chong Hwa Kim, Soo Heon Kwak, Yong‐ho Lee, Choon Hee Chung, Sihoon Lee, Heung Yong Jin, Jae Hyuk Lee, Gwanpyo Koh, Sang-Yong Kim, Jaetaek Kim, Ju Hee Lee, Tae Nyun Kim, Hyun Jeong Jeon, Ji Hyun Lee, Jae-Han Jeon, Hye Jin Yoo, Hee Kyung Kim, Hyeong-Kyu Park, Il Seong Nam-Goong, Seongbin Hong, Chul Woo Ahn, Ji Hee Yu, Jong Heon Park, Keun-Gyu Park, Chan Ho Park, Kyong Hye Joung, Ohk-Hyun Ryu, Keun Yong Park, Eun-Gyoung Hong, Bong-Soo Cha, Kyu Chang Won, Yoon-Sok Chung, Sin Gon Kim
-
Endocrinol Metab. 2024;39(5):722-731. Published online August 22, 2024
-
DOI: https://doi.org/10.3803/EnM.2024.1995
-
-
 Abstract
 PDF PubReader  ePub
- Background
Atherogenic dyslipidemia, which is frequently associated with type 2 diabetes (T2D) and insulin resistance, contributes to the development of vascular complications. Statin therapy is the primary approach to dyslipidemia management in T2D, however, the role of non-statin therapy remains unclear. Ezetimibe reduces cholesterol burden by inhibiting intestinal cholesterol absorption. Fibrates lower triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C) levels via peroxisome proliferator- activated receptor alpha agonism. Therefore, when combined, these drugs effectively lower non-HDL-C levels. Despite this, few clinical trials have specifically targeted non-HDL-C, and the efficacy of triple combination therapies, including statins, ezetimibe, and fibrates, has yet to be determined.
Methods
This is a multicenter, prospective, randomized, open-label, active-comparator controlled trial involving 3,958 eligible participants with T2D, cardiovascular risk factors, and elevated non-HDL-C (≥100 mg/dL). Participants, already on moderate-intensity statins, will be randomly assigned to either Ezefeno (ezetimibe/fenofibrate) addition or statin dose-escalation. The primary end point is the development of a composite of major adverse cardiovascular and diabetic microvascular events over 48 months.
Conclusion
This trial aims to assess whether combining statins, ezetimibe, and fenofibrate is as effective as, or possibly superior to, statin monotherapy intensification in lowering cardiovascular and microvascular disease risk for patients with T2D. This could propose a novel therapeutic approach for managing dyslipidemia in T2D.
- Diabetes, obesity and metabolism
- Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease
-
Hun Jee Choe, Yeh-Hee Ko, Sun Joon Moon, Chang Ho Ahn, Kyoung Hwa Ha, Hyeongsuk Lee, Jae Hyun Bae, Hyung Joon Joo, Hyejin Lee, Jang Wook Son, Dae Jung Kim, Sin Gon Kim, Kwangsoo Kim, Young Min Cho
-
Endocrinol Metab. 2024;39(4):622-631. Published online August 1, 2024
-
DOI: https://doi.org/10.3803/EnM.2024.1965
-
-
Abstract
PDF
 Supplementary MaterialPubReader ePub
- Background
Dipeptidyl peptidase-4 (DPP4) inhibitors are frequently prescribed for patients with type 2 diabetes; however, their cost can pose a significant barrier for those with impaired kidney function. This study aimed to estimate the economic benefits of substituting non-renal dose-adjusted (NRDA) DPP4 inhibitors with renal dose-adjusted (RDA) DPP4 inhibitors in patients with both impaired kidney function and type 2 diabetes.
Methods
This retrospective cohort study was conducted from January 1, 2012 to December 31, 2018, using data obtained from common data models of five medical centers in Korea. Model 1 applied the prescription pattern of participants with preserved kidney function to those with impaired kidney function. In contrast, model 2 replaced all NRDA DPP4 inhibitors with RDA DPP4 inhibitors, adjusting the doses of RDA DPP4 inhibitors based on individual kidney function. The primary outcome was the cost difference between the two models.
Results
In total, 67,964,996 prescription records were analyzed. NRDA DPP4 inhibitors were more frequently prescribed to patients with impaired kidney function than in those with preserved kidney function (25.7%, 51.3%, 64.3%, and 71.6% in patients with estimated glomerular filtration rates [eGFRs] of ≥60, <60, <45, and <30 mL/min/1.73 m2, respectively). When model 1 was applied, the cost savings per year were 7.6% for eGFR <60 mL/min/1.73 m2 and 30.4% for eGFR <30 mL/min/1.73 m2. According to model 2, 15.4% to 51.2% per year could be saved depending on kidney impairment severity.
Conclusion
Adjusting the doses of RDA DPP4 inhibitors based on individual kidney function could alleviate the economic burden associated with medical expenses.
- Thyroid
- Treatment Patterns and Preferences for Graves’ Disease in Korea: Insights from a Nationwide Cohort Study
-
Kyeong Jin Kim, Jimi Choi, Soo Myoung Shin, Jung A Kim, Kyoung Jin Kim, Sin Gon Kim
-
Endocrinol Metab. 2024;39(4):659-663. Published online August 5, 2024
-
DOI: https://doi.org/10.3803/EnM.2024.2042
-
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Treatment patterns and preferences for patients with Graves’ disease (GD) vary across countries. In this study, we assessed the initial therapies and subsequent treatment modalities employed for GD in real-world clinical practice in Korea. We analyzed 452,001 patients with GD from 2004 to 2020, obtained from the Korean National Health Insurance Service database. Initial treatments included antithyroid drug (ATD) therapy (98% of cases), thyroidectomy (1.3%), and radioactive iodine (RAI) therapy (0.7%). The rates of initial treatment failure were 58.5% for ATDs, 21.3% for RAI, and 2.1% for thyroidectomy. Even among cases of ATD treatment failure or recurrence, the rates of RAI therapy remained low. Regarding initial treatment, the 5-year remission rate was 46.8% among patients administered ATDs versus 91.0% among recipients of RAI therapy; at 10 years, these rates were 59.2% and 94.0%, respectively. Our findings highlight a marked disparity in the use of RAI therapy in Korea compared to Western countries. Further research is required to understand the reasons for these differences in treatment patterns.
- Calcium & bone metabolism
Big Data Articles (National Health Insurance Service Database)
- Increased Risk of Hip Fracture in Patients with Acromegaly: A Nationwide Cohort Study in Korea
-
Jiwon Kim, Namki Hong, Jimi Choi, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Sin Gon Kim, Cheol Ryong Ku
-
Endocrinol Metab. 2023;38(6):690-700. Published online October 30, 2023
-
DOI: https://doi.org/10.3803/EnM.2023.1782
-
-
2,597
View
-
120
Download
-
1
Web of Science
-
1
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Acromegaly leads to various skeletal complications, and fragility fractures are emerging as a new concern in patients with acromegaly. Therefore, this study investigated the risk of fractures in Korean patients with acromegaly.
Methods
We used the Korean nationwide claims database from 2009 to 2019. A total of 931 patients with acromegaly who had never used an osteoporosis drug before and were treated with surgery alone were selected as study participants, and a 1:29 ratio of 26,999 age- and sex-matched osteoporosis drug-naïve controls without acromegaly were randomly selected from the database.
Results
The mean age was 46.2 years, and 50.0% were male. During a median follow-up of 54.1 months, there was no difference in the risks of all, vertebral, and non-vertebral fractures between the acromegaly and control groups. However, hip fracture risk was significantly higher (hazard ratio [HR], 2.73; 95% confidence interval [CI], 1.32 to 5.65), and non-hip and non-vertebral fractures risk was significantly lower (HR, 0.40; 95% CI, 0.17 to 0.98) in patients with acromegaly than in controls; these results remained robust even after adjustment for socioeconomic status and baseline comorbidities. Age, type 2 diabetes mellitus, cardio-cerebrovascular disease, fracture history, recent use of acid-suppressant medication, psychotropic medication, and opioids were risk factors for all fractures in patients with acromegaly (all P<0.05).
Conclusion
Compared with controls, patients surgically treated for acromegaly had a higher risk of hip fractures. The risk factors for fracture in patients with acromegaly were consistent with widely accepted risk factors in the general population.
-
Citations
Citations to this article as recorded by  - Novel approach to bone comorbidity in resistant acromegaly
Stefano Frara, Matteo Acanfora, Vincenzo Franzese, Maria Luisa Brandi, Marco Losa, Andrea Giustina
Pituitary.2024;[Epub] CrossRef
- Diabetes, Obesity and Metabolism
- Sleep Duration and the Risk of Type 2 Diabetes: A Community-Based Cohort Study with a 16-Year Follow-up
-
Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Seung Ku Lee, Chol Shin, Nan Hee Kim
-
Endocrinol Metab. 2023;38(1):146-155. Published online February 6, 2023
-
DOI: https://doi.org/10.3803/EnM.2022.1582
-
-
4,078
View
-
197
Download
-
7
Web of Science
-
9
Crossref
-
Abstract
PDFPubReader ePub
- Background
We aimed to investigate the moderating effects of obesity, age, and sex on the association between sleep duration and the development of diabetes in Asians.
Methods
We analyzed data from a cohort of the Korean Genome and Epidemiology Study conducted from 2001 to 2020. After excluding shift workers and those with diabetes at baseline, 7,407 participants were stratified into three groups according to sleep duration: ≤5 hours/night, >5 to 7 hours/night (reference), and >7 hours/night. The Cox proportional hazards analyses were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes mellitus (T2DM). Subgroup analyses were performed according to obesity, age, and sex.
Results
During 16 years of follow-up, 2,024 cases of T2DM were identified. Individuals who slept ≤5 h/night had a higher risk of incident diabetes than the reference group (HR, 1.17; 95% CI, 1.02 to 1.33). The subgroup analysis observed a valid interaction with sleep duration only for obesity. A higher risk of T2DM was observed in the ≤5 hours/night group in non-obese individuals, men, and those aged <60 years, and in the >7 hours/night group in obese individuals (HRs were 1.34 [95% CI, 1.11 to 1.61], 1.22 [95% CI, 1 to 1.49], and 1.18 [95% CI, 1.01 to 1.39], respectively).
Conclusion
This study confirmed the effect of sleep deprivation on the risk of T2DM throughout the 16-year follow-up period. This impact was confined to non-obese or young individuals and men. We observed a significant interaction between sleep duration and obesity.
-
Citations
Citations to this article as recorded by - Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes
Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim
Diabetes & Metabolism Journal.2024; 48(1): 37. CrossRef - Role of Sleep and Sleep Disorders in Cardiometabolic Risk: a Review and Update
Shaden O. Qasrawi, Ahmed S. BaHammam
Current Sleep Medicine Reports.2024; 10(1): 34. CrossRef - Evaluating reliability in wearable devices for sleep staging
Vera Birrer, Mohamed Elgendi, Olivier Lambercy, Carlo Menon
npj Digital Medicine.2024;[Epub] CrossRef - Replication Study of Genome Wide Association Study of Sleep Duration in Korean Association Resources Cohort
Seok-Ho Cho, Seon-Ah Kim, Hyun-Seok Jin, Hong Sung Kim
Biomedical Science Letters.2024; 30(2): 86. CrossRef - Insights into optimal BMI from the GlasVEGAS study
Chun-Kwan O, Juliana C. N. Chan
Nature Metabolism.2024; 6(8): 1435. CrossRef - Mechanisms, consequences and role of interventions for sleep deprivation: Focus on mild cognitive impairment and Alzheimer’s disease in elderly
Upasana Mukherjee, Ujala Sehar, Malcolm Brownell, P. Hemachandra Reddy
Ageing Research Reviews.2024; 100: 102457. CrossRef - The Relationship Between the Risk of Type 2 Diabetes and Insomnia Severity and Sleep Duration in Academicians
Tuğba Bilgehan, Esra Çalık Var
Sağlık Bilimleri Üniversitesi Hemşirelik Dergisi.2024;[Epub] CrossRef - All That Glitters Is Not Gold: The Same Sleep Time, but Different Diabetogenic Outcomes
Bohye Kim, Obin Kwon
Endocrinology and Metabolism.2023; 38(1): 78. CrossRef - The Link Between Sleeping and Type 2 Diabetes: A Systematic Review
Ali Darraj
Cureus.2023;[Epub] CrossRef
- Diabetes, Obesity and Metabolism
- Identification of Healthy and Unhealthy Lifestyles by a Wearable Activity Tracker in Type 2 Diabetes: A Machine Learning-Based Analysis
-
Kyoung Jin Kim, Jung-Been Lee, Jimi Choi, Ju Yeon Seo, Ji Won Yeom, Chul-Hyun Cho, Jae Hyun Bae, Sin Gon Kim, Heon-Jeong Lee, Nam Hoon Kim
-
Endocrinol Metab. 2022;37(3):547-551. Published online June 29, 2022
-
DOI: https://doi.org/10.3803/EnM.2022.1479
-
-
3,751
View
-
133
Download
-
2
Web of Science
-
3
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Lifestyle is a critical aspect of diabetes management. We aimed to define a healthy lifestyle using objectively measured parameters obtained from a wearable activity tracker (Fitbit) in patients with type 2 diabetes. This prospective observational study included 24 patients (mean age, 46.8 years) with type 2 diabetes. Expectation–maximization clustering analysis produced two groups: A (n=9) and B (n=15). Group A had a higher daily step count, lower resting heart rate, longer sleep duration, and lower mean time differences in going to sleep and waking up than group B. A Shapley additive explanation summary analysis indicated that sleep-related factors were key elements for clustering. The mean hemoglobin A1c level was 0.3 percentage points lower at the end of follow-up in group A than in group B. Factors related to regular sleep patterns could be possible determinants of lifestyle clustering in patients with type 2 diabetes.
-
Citations
Citations to this article as recorded by - Evaluating impact of movement on diabetes via artificial intelligence and smart devices systematic literature review
Sayna Rotbei, Wei Hsuan Tseng, Beatriz Merino-Barbancho, Muhammad Salman Haleem, Luis Montesinos, Leandro Pecchia, Giuseppe Fico, Alessio Botta
Expert Systems with Applications.2024; 257: 125058. CrossRef - Rethink nutritional management in chronic kidney disease care
Fangyue Chen, Krit Pongpirul
Frontiers in Nephrology.2023;[Epub] CrossRef - Effect of a Wearable Device–Based Physical Activity Intervention in North Korean Refugees: Pilot Randomized Controlled Trial
Ji Yoon Kim, Kyoung Jin Kim, Kyeong Jin Kim, Jimi Choi, Jinhee Seo, Jung-Been Lee, Jae Hyun Bae, Nam Hoon Kim, Hee Young Kim, Soo-Kyung Lee, Sin Gon Kim
Journal of Medical Internet Research.2023; 25: e45975. CrossRef
- Adrenal Gland
Big Data Articles (National Health Insurance Service Database)
- Epidemiology and Long-Term Adverse Outcomes in Korean Patients with Congenital Adrenal Hyperplasia: A Nationwide Study
-
Jung Hee Kim, Sunkyu Choi, Young Ah Lee, Juneyoung Lee, Sin Gon Kim
-
Endocrinol Metab. 2022;37(1):138-147. Published online February 28, 2022
-
DOI: https://doi.org/10.3803/EnM.2021.1328
-
-
4,726
View
-
174
Download
-
11
Web of Science
-
12
Crossref
-
Abstract
PDFPubReader ePub
- Background
Previous studies on the epidemiology and complications of congenital adrenal hyperplasia (CAH) were conducted in Western countries and in children/adolescents. We aimed to explore the epidemiology of CAH, as well as the risk of comorbidities and mortality, in a Korean nationwide case-control study.
Methods
CAH patients (n=2,840) were included between 2002 and 2017 from the National Health Insurance Service database and the Rare Intractable Disease program. CAH patients were compared, at a 1:10 ratio, with age-, sex-, and index year-matched controls (n=28,400).
Results
The point prevalence of CAH patients in Korea was 1 in 18,745 persons in 2017. The annual incidence rate declined between 2003 and 2017 from 3.25 to 0.41 per 100,000 persons. CAH patients were at elevated risk for cardiovascular disease (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.4 to 1.9), stroke (OR, 1.7; 95% CI, 1.3 to 2.0), diabetes mellitus (OR, 2.8; 95% CI, 2.6 to 3.1), dyslipidemia (OR, 2.4; 95% CI, 2.2 to 2.6), and psychiatric disorders (OR, 1.5; 95% CI, 1.3 to 1.6). Fracture risk increased in CAH patients aged over 40 years (OR, 1.4; 95% CI, 1.1 to 1.7). CAH patients were at higher risk of mortality than controls (hazard ratio, 1.6; 95% CI, 1.3 to 2.0).
Conclusion
Our nationwide study showed a recent decline in the incidence of CAH and an elevated risk for cardiovascular, metabolic, skeletal, and psychiatric disorders in CAH patients. Lifelong management for comorbidity risk is a crucial component of treating CAH patients.
-
Citations
Citations to this article as recorded by - Long‐term health consequences of congenital adrenal hyperplasia
Riccardo Pofi, Xiaochen Ji, Nils P. Krone, Jeremy W. Tomlinson
Clinical Endocrinology.2024; 101(4): 318. CrossRef - Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women—What Is the Evidence?
Angelica Lindén Hirschberg
The Journal of Clinical Endocrinology & Metabolism.2024; 109(5): 1202. CrossRef - Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Suranut Charoensri, Richard J Auchus
The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1133. CrossRef - Case report: Development of central precocious puberty in a girl with late-diagnosed simple virilizing congenital adrenal hyperplasia complicated with Williams syndrome
Eun Young Joo, Myung Ji Yoo, Su Jin Kim, Woori Jang, Ji-Eun Lee
Frontiers in Endocrinology.2024;[Epub] CrossRef - Cardiometabolic Aspects of Congenital Adrenal Hyperplasia
Robert Krysiak, Hedi L Claahsen-van der Grinten, Nicole Reisch, Philippe Touraine, Henrik Falhammar
Endocrine Reviews.2024;[Epub] CrossRef - Proof of concept for a superior therapeutic index of corticosterone compared with hydrocortisone in patients with congenital adrenal hyperplasia
Catriona J Kyle, Luke D Boyle, Mark Nixon, Natalie Z M Homer, Joanna P Simpson, Alison Rutter, Lynne E Ramage, Alexandra Kelman, Ellen Marie Freel, Ruth Andrew, Brian R Walker, Roland H Stimson
European Journal of Endocrinology.2024; 191(6): 535. CrossRef - Анализ распространенности и заболеваемости надпочечниковой недостаточностью в мире
М. Ю. Юкина, Н. Ф. Нуралиева, Е. А. Трошина
Ateroscleroz.2023; 18(4): 426. CrossRef - Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2023; 38(1): 10. CrossRef - Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia
Beatrice Righi, Salma R. Ali, Jillian Bryce, Jeremy W. Tomlinson, Walter Bonfig, Federico Baronio, Eduardo C. Costa, Guilherme Guaragna-Filho, Guy T’Sjoen, Martine Cools, Renata Markosyan, Tania A. S. S. Bachega, Mirela C. Miranda, Violeta Iotova, Henrik
Endocrine.2023; 80(3): 630. CrossRef - Serum steroid profile captures metabolic phenotypes in adults with classic congenital adrenal hyperplasia
Chang Ho Ahn, Jaeyoon Shim, Han Na Jang, Young Ah Lee, Sang-Won Lee, Man Ho Choi, Jung Hee Kim
The Journal of Steroid Biochemistry and Molecular Biology.2023; 234: 106374. CrossRef - Multiplexed Serum Steroid Profiling Reveals Metabolic Signatures of Subtypes in Congenital Adrenal Hyperplasia
Jaeyoon Shim, Chang Ho Ahn, Seung Shin Park, Jongsung Noh, Chaelin Lee, Sang Won Lee, Jung Hee Kim, Man Ho Choi
Journal of the Endocrine Society.2023;[Epub] CrossRef - Long-Term Outcomes of Congenital Adrenal Hyperplasia
Anna Nordenström, Svetlana Lajic, Henrik Falhammar
Endocrinology and Metabolism.2022; 37(4): 587. CrossRef
- Diabetes, Obesity and Metabolism
- How Can We Adopt the Glucose Tolerance Test to Facilitate Predicting Pregnancy Outcome in Gestational Diabetes Mellitus?
-
Kyeong Jin Kim, Nam Hoon Kim, Jimi Choi, Sin Gon Kim, Kyung Ju Lee
-
Endocrinol Metab. 2021;36(5):988-996. Published online October 15, 2021
-
DOI: https://doi.org/10.3803/EnM.2021.1107
-
-
5,171
View
-
119
Download
-
2
Web of Science
-
2
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
We investigated how 100-g oral glucose tolerance test (OGTT) results can be used to predict adverse pregnancy outcomes in gestational diabetes mellitus (GDM) patients.
Methods
We analyzed 1,059 pregnant women who completed the 100-g OGTT between 24 and 28 weeks of gestation. We compared the risk of adverse pregnancy outcomes according to OGTT patterns by latent profile analysis (LPA), numbers to meet the OGTT criteria, and area under the curve (AUC) of the OGTT graph. Adverse pregnancy outcomes were defined as a composite of preterm birth, macrosomia, large for gestational age, low APGAR score at 1 minute, and pregnancy-induced hypertension.
Results
Overall, 257 participants were diagnosed with GDM, with a median age of 34 years. An LPA led to three different clusters of OGTT patterns; however, there were no significant associations between the clusters and adverse pregnancy outcomes after adjusting for confounders. Notwithstanding, the risk of adverse pregnancy outcome increased with an increase in number to meet the OGTT criteria (P for trend=0.011); odds ratios in a full adjustment model were 1.27 (95% confidence interval [CI], 0.72 to 2.23), 2.16 (95% CI, 1.21 to 3.85), and 2.32 (95% CI, 0.66 to 8.15) in those meeting the 2, 3, and 4 criteria, respectively. The AUCs of the OGTT curves also distinguished the patients at risk of adverse pregnancy outcomes; the larger the AUC, the higher the risk (P for trend=0.007).
Conclusion
The total number of abnormal values and calculated AUCs for the 100-g OGTT may facilitate tailored management of patients with GDM by predicting adverse pregnancy outcomes.
-
Citations
Citations to this article as recorded by - Risk factors combine in a complex manner in assessment for macrosomia
Yi-Wen Wang, Yan Chen, Yong-Jun Zhang
BMC Public Health.2023;[Epub] CrossRef - Association of the Severity of Hypertensive Disorders in Pregnancy with Birthweight, Childhood Obesity, and Blood Pressure at Age 7
Yan Chen, Yiwen Wang, Yanjun Li, Guodong Ding, Yongjun Zhang
Nutrients.2023; 15(14): 3104. CrossRef
- Clinical Study
- Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
-
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
-
Endocrinol Metab. 2021;36(2):388-400. Published online March 31, 2021
-
DOI: https://doi.org/10.3803/EnM.2020.912
-
-
7,918
View
-
392
Download
-
14
Web of Science
-
17
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes.
Methods
We searched electronic databases (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials) from inception to June 2019 to identity eligible randomized controlled trials of DPP-4 inhibitors or SGLT2 inhibitors that reported at least one kidney outcome in patients with type 2 diabetes. Outcomes of interest were microalbuminuria, macroalbuminuria, worsening nephropathy, and end-stage kidney disease (ESKD). We performed an arm-based network meta-analysis using Bayesian methods and calculated absolute risks and rank probabilities of each treatment for the outcomes.
Results
Seventeen studies with 87,263 patients were included. SGLT2 inhibitors significantly lowered the risks of individual kidney outcomes, including microalbuminuria (odds ratio [OR], 0.64; 95% credible interval [CrI], 0.41 to 0.93), macroalbuminuria (OR, 0.48; 95% CrI, 0.24 to 0.72), worsening nephropathy (OR, 0.65; 95% CrI, 0.44 to 0.91), and ESKD (OR, 0.65; 95% CrI, 0.46 to 0.98) as compared with placebo. However, DPP-4 inhibitors did not lower the risks. SGLT2 inhibitors were considerably associated with higher absolute risk reductions in all kidney outcomes than DPP-4 inhibitors, although the benefits were statistically insignificant. The rank probabilities showed that SGLT2 inhibitors were better treatments for lowering the risk of albuminuria and ESKD than placebo or DPP-4 inhibitors.
Conclusion
SGLT2 inhibitors were superior to DPP-4 inhibitors in reducing the risk of albuminuria and ESKD in patients with type 2 diabetes.
-
Citations
Citations to this article as recorded by - Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2024; 20(2): 212. CrossRef - Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
Cardiovascular Diabetology.2024;[Epub] CrossRef - Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh
Diabetes & Metabolism Journal.2024; 48(2): 312. CrossRef - Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Experimental and Clinical Endocrinology & Diabetes.2024; 132(07): 340. CrossRef - Clinical Management of Type II DM in patients Showing Progressive Increase in the Creatinine Level – A Cross-sectional Study
Prabhudatta Mohapatra, Durga Madhab Kar, Karmajeet Rath, Abhisek Pal
Research Journal of Pharmacy and Technology.2024; : 2719. CrossRef - Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2023; 19(5): 658. CrossRef - Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
Apichaya Chanawong, Suriyon Uitrakul, Supatcha Incomenoy, Natnicha Poonchuay, Rizky Abdulah
Advances in Pharmacological and Pharmaceutical Sciences.2023; 2023: 1. CrossRef - Different nursing interventions on sleep quality among critically ill patients: A systematic review and network meta-analysis
Daijin Huang, Yumei Li, Jing Ye, Chang Liu, Dongyan Shen, Yunhui Lv
Medicine.2023; 102(52): e36298. CrossRef - New trends in the approach to the treatment of type 2 diabetes - observations and benefits in the outpatient practice of a diabetologist
Pavel Weber, Hana Meluzínová, Dana Weberová
Klinická farmakologie a farmacie.2022; 35(4): 118. CrossRef - Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis
Hongwei Cao, Tao Liu, Li Wang, Qiuhe Ji
Diabetes, Obesity and Metabolism.2022; 24(8): 1448. CrossRef - Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2022; 18(5): 623. CrossRef - Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on inte
Iskandar Idris, Ruiqi Zhang, Jil B. Mamza, Mike Ford, Tamsin Morris, Amitava Banerjee, Kamlesh Khunti
Diabetes, Obesity and Metabolism.2022; 24(11): 2138. CrossRef - Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Experimental and Clinical Endocrinology & Diabetes.2022; 130(S 01): S80. CrossRef - Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease
Kaixuan Zhou, Xue Zi, Jiayu Song, Qiulu Zhao, Jia Liu, Huiwei Bao, Lijing Li
Molecules.2022; 27(19): 6221. CrossRef - Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Jiandong Zhou, Xuejin Liu, Oscar Hou-In Chou, Lifang Li, Sharen Lee, Wing Tak Wong, Qingpeng Zhang, Carlin Chang, Tong Liu, Gary Tse, Fengshi Jing, Bernard Man Yung Cheung
Rheumatology.2022;[Epub] CrossRef - New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
Chan-Hee Jung
Endocrinology and Metabolism.2021; 36(2): 339. CrossRef - Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André J. Scheen
Diabetes & Metabolism.2021; 47(6): 101275. CrossRef
- Clinical Study
- Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea
-
Hwa Young Ahn, Jae Eun Chae, Hyemi Moon, Junghyun Noh, Young Joo Park, Sin Gon Kim
-
Endocrinol Metab. 2020;35(4):811-819. Published online November 20, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.709
-
-
7,522
View
-
207
Download
-
16
Web of Science
-
15
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Thyroid cancer is becoming increasingly common worldwide, but little is known about the epidemiology of medullary thyroid carcinoma (MTC). This study investigated the current status of the incidence and treatment of MTC using Korean National Health Insurance Service (NHIS) data for the entire Korean population from 2004 to 2016.
Methods
This study included 1,790 MTC patients identified from the NHIS database.
Results
The age-standardized incidence rate showed a slightly decreasing or stationary trend during the period, from 0.25 per 100,000 persons in 2004 to 0.19 in 2016. The average proportion of MTC among all thyroid cancers was 0.5%. For initial surgical treatment, 65.4% of patients underwent total thyroidectomy. After surgery, external-beam radiation therapy (EBRT) was performed in 10% of patients, a proportion that increased from 6.7% in 2004 to 11.0% in 2016. Reoperations were performed in 2.7% of patients (n=49) at a median of 1.9 years of follow-up (interquartile range, 1.2 to 3.4). Since November 2015, 25 (1.4%) patients with MTC were prescribed vandetanib by December 2016.
Conclusion
The incidence of MTC decreased slightly with time, and the proportion of patients who underwent total thyroidectomy was about 65%. EBRT, reoperation, and tyrosine kinase inhibitor therapy are additional treatments after initial surgery for advanced MTC in Korea.
-
Citations
Citations to this article as recorded by - Treatment and management of medullary thyroid microcarcinoma: a 10-year retrospective study from a single center
Bin Liu, Ying Peng, Yanjun Su, Chang Diao, Ruochuan Cheng
Endocrine.2024; 86(3): 1081. CrossRef - Management of Giant Thyroid Tumors in Patients with Multiple Comorbidities in a Tertiary Head and Neck Surgery Center
Daniela Vrinceanu, Mihai Dumitru, Andreea Marinescu, Crenguta Serboiu, Gabriela Musat, Mihai Radulescu, Matei Popa-Cherecheanu, Catalina Ciornei, Felicia Manole
Biomedicines.2024; 12(10): 2204. CrossRef - Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2023; 38(1): 10. CrossRef - Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma
Chan Kwon Jung, Shipra Agarwal, Jen-Fan Hang, Dong-Jun Lim, Andrey Bychkov, Ozgur Mete
Endocrine Pathology.2023; 34(1): 1. CrossRef - Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates
Hye Choi, Kwangsoon Kim
International Journal of Molecular Sciences.2023; 24(13): 11138. CrossRef - Partial preservation of the normal thyroid gland based on tumor diameter may be possible in small medullary thyroid carcinoma: a two-center 15-year retrospective study
Guiming Fu, Xiaoyi Li, Fengli Guo, Xianhui Ruan, Wei Zhang, Weijing Zhang, Yaping Zhang, Yibo Chen, Chunhua Li, Jin Chen, Xiangqian Zheng, Zhaohui Wang, Ming Gao
Frontiers in Oncology.2023;[Epub] CrossRef - Association of Socioeconomic Status With Long-Term Outcome in Survivors After Out-of-Hospital Cardiac Arrest: Nationwide Population-Based Longitudinal Study
Kyung Hun Yoo, Yongil Cho, Jaehoon Oh, Juncheol Lee, Byuk Sung Ko, Hyunggoo Kang, Tae Ho Lim, Sang Hwan Lee
JMIR Public Health and Surveillance.2023; 9: e47156. CrossRef - Preoperative identification of low-risk medullary thyroid carcinoma: potential application to reduce total thyroidectomy
Hyunju Park, Hyun Jin Ryu, Jung Heo, Man Ki Chung, Young Ik Son, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Sun Wook Kim, Jae Hoon Chung, Jee Soo Kim, Tae Hyuk Kim
Scientific Reports.2023;[Epub] CrossRef - Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study
Xin Wu, Binglu Li, Chaoji Zheng
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef - Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research
Dae-Sung Kyoung, Hun-Sung Kim
Journal of Lipid and Atherosclerosis.2022; 11(2): 103. CrossRef - Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines
Daqi Zhang, Carla Colombo, Hui Sun, Hoon Yub Kim, Antonella Pino, Simone De Leo, Giacomo Gazzano, Luca Persani, Gianlorenzo Dionigi, Laura Fugazzola
Frontiers in Endocrinology.2022;[Epub] CrossRef - Total thyroidectomy vs thyroid lobectomy for localized medullary thyroid cancer in adults: A propensity-matched survival analysis
Weili Liang, Jinyuan Shi, Hui Zhang, Guixu Lv, Tiantian Wang, Yong Wang, Bin Lv, Luchuan Li, Qingdong Zeng, Lei Sheng
Surgery.2022; 172(5): 1385. CrossRef - Constitutive Cytomorphologic Features of Medullary Thyroid Carcinoma Using Different Staining Methods
Chih-Yi Liu, Chien-Chin Chen, Andrey Bychkov, Shipra Agarwal, Yun Zhu, Jen-Fan Hang, Chiung-Ru Lai, Hee Young Na, So Yeon Park, Weiwei Li, Zhiyan Liu, Deepali Jain, Ayana Suzuki, Mitsuyoshi Hirokawa, Noel Chia, Min En Nga, Tikamporn Jitpasutham, Somboon K
Diagnostics.2021; 11(8): 1396. CrossRef - Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer
Jinyoung Kim, Jun Park, Hyunju Park, Min Sun Choi, Hye Won Jang, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung
Cancers.2021; 13(22): 5842. CrossRef - A High Frequency of Lobectomy Instead of Total Thyroidectomy to Treat Medullary Thyroid Cancer in Korea: Data from the Korean National Health Insurance Service
Sun Wook Cho
Endocrinology and Metabolism.2020; 35(4): 784. CrossRef
- Clinical Study
- Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service
-
Jung Hee Kim, Hyemi Moon, Junghyun Noh, Juneyoung Lee, Sin Gon Kim
-
Endocrinol Metab. 2020;35(1):157-164. Published online March 19, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.35.1.157
-
-
8,632
View
-
200
Download
-
30
Web of Science
-
27
Crossref
-
Abstract
PDFPubReader ePub
- Background
Pheochromocytomas and paragangliomas (PPGLs) are rare endocrine tumors originating from chromaffin cells. PPGLs are associated with a high mortality rate and several complications. To date, no epidemiological studies have been conducted on PPGLs in Asia. This study aimed to investigate the epidemiology and prognosis of PPGLs in Korea using nationwide data. MethodsUsing the National Health Insurance Service Database, subjects with a principal diagnosis of PPGLs on two or more occasions between 2003 and 2014 who satisfied the operational definition of PPGLs were included. Incidence, prevalence, complications, metastasis, and mortality were investigated. ResultsIn total, 1048 subjects with a mean age of 47.6±16.1 years were included. There was no sex preponderance. The overall prevalence of PPGLs was 2.13 per 100,000 persons, and the overall age-standardized incidence rate was 0.18 per 100,000 person-years. Malignant PPGLs accounted for 17.7% (185 of 1,048) of cases, and 94 subjects exhibited metastasis at the time of diagnosis. Among initially non-metastatic PPGLs, 9.5% (nine of 954) eventually metastasized after a mean duration of 78.1±41.4 months. The 5-year survival rates for non-metastatic and metastatic PPGLs at diagnosis were 97% and 84%, respectively. Multivariable Cox regression models adjusted for covariates showed that metastatic PPGLs were associated with a 2.40-fold higher risk of mortality than non-metastatic PPGLs (95% confidence interval, 1.38 to 4.17; P=0.002). ConclusionPPGLs are rare in Korea, and the prognosis of these endocrine tumors varies depending on whether they are benign or malignant. This epidemiological study paves the way for further research on PPGLs.
-
Citations
Citations to this article as recorded by - Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study
Seung Shin Park, Chang Ho Ahn, Seunghoo Lee, Woochang Lee, Won Woong Kim, Yu‐Mi Lee, Su Jin Kim, Tae‐Yon Sung, Kyu Eun Lee, Jung Hee Kim, Seung Hun Lee, Jung‐Min Koh
Journal of Internal Medicine.2024; 296(1): 68. CrossRef - Seventy years of pheochromocytomas and paragangliomas in Argentina. The FRENAR database
V.C. de Miguel, L.S. Aparicio, G. Sansó, A.L. Paissan, S.N. Lupi, S.H. Belli, J. Tkatch, M.J. Marín, M.B. Barontini
Hipertensión y Riesgo Vascular.2024; 41(3): 170. CrossRef - Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients
Wolfgang Raber, Raphael Schendl, Melisa Arikan, Andreas Scheuba, Peter Mazal, Valerie Stadlmann, Reinhard Lehner, Petra Zeitlhofer, Sabina Baumgartner-Parzer, Cornelia Gabler, Harald Esterbauer
Frontiers in Endocrinology.2024;[Epub] CrossRef - Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2023; 38(1): 10. CrossRef - Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician
Sona Sharma, Lauren Fishbein
Endocrine Practice.2023; 29(12): 999. CrossRef - Pheochromocytoma: a changing perspective and current concepts
Andreas Kiriakopoulos, Periklis Giannakis, Evangelos Menenakos
Therapeutic Advances in Endocrinology and Metabolism.2023;[Epub] CrossRef - Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas
Gildas Gabiache, Charline Zadro, Laura Rozenblum, Delphine Vezzosi, Céline Mouly, Matthieu Thoulouzan, Rosine Guimbaud, Philippe Otal, Lawrence Dierickx, Hervé Rousseau, Christopher Trepanier, Laurent Dercle, Fatima-Zohra Mokrane
Cancers.2023; 15(18): 4666. CrossRef - Trends in the incidence of adrenocortical carcinoma and pheochromocytoma/paraganglioma in Taiwan
Chung-Hsin Tsai, Tun-Sung Huang, Shih-Ping Cheng
Formosan Journal of Surgery.2023;[Epub] CrossRef - An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
Anri Inaki, Tohru Shiga, Yoshito Tsushima, Megumi Jinguji, Hiroshi Wakabayashi, Daiki Kayano, Norihito Akatani, Takafumi Yamase, Yuji Kunita, Satoru Watanabe, Tomo Hiromasa, Hiroshi Mori, Kenji Hirata, Shiro Watanabe, Tetsuya Higuchi, Hiroyasu Tomonaga, S
Annals of Nuclear Medicine.2022; 36(3): 267. CrossRef - Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance
Jan Calissendorff, Carl Christofer Juhlin, Irina Bancos, Henrik Falhammar
Cancers.2022; 14(4): 917. CrossRef - Characteristics of Intraoperative Hemodynamic Instability in Postoperatively Diagnosed Pheochromocytoma and Sympathetic Paraganglioma Patients
Jung Hee Kim, Hyung-Chul Lee, Su-jin Kim, Kyu Eun Lee, Kyeong Cheon Jung
Frontiers in Endocrinology.2022;[Epub] CrossRef - Change of Computed Tomography-Based Body Composition after Adrenalectomy in Patients with Pheochromocytoma
Yousun Ko, Heeryoel Jeong, Seungwoo Khang, Jeongjin Lee, Kyung Won Kim, Beom-Jun Kim
Cancers.2022; 14(8): 1967. CrossRef - Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years
Abdul Rahman Al Subhi, Veronica Boyle, Marianne S Elston
Journal of the Endocrine Society.2022;[Epub] CrossRef - Incidence and risk factors for myocardial injury after laparoscopic adrenalectomy for pheochromocytoma: A retrospective cohort study
Ling Lan, Qian Shu, Chunhua Yu, Lijian Pei, Yuelun Zhang, Li Xu, Yuguang Huang
Frontiers in Oncology.2022;[Epub] CrossRef - The Clinical Characteristics of Pheochromocytomas and Paragangliomas with Negative Catecholamines
Lin Zhao, Xiaoran Zhang, Xu Meng, Ting Zhang, Hua Fan, Qiongyu Zhang, Yecheng Liu, Xianliang Zhou, Huadong Zhu
Journal of Clinical Medicine.2022; 11(19): 5583. CrossRef - A midline ectopic paraganglioma
Christina SANT FOURNIER, Matthias FARRUGIA, Kimberley PACE, Christian CAMENZULI, Alexander R. ATTARD
Chirurgia.2022;[Epub] CrossRef - Non-Selective Alpha-Blockers Provide More Stable Intraoperative Hemodynamic Control Compared with Selective Alpha1-Blockers in Patients with Pheochromocytoma and Paraganglioma: A Single-Center Retrospective Cohort Study with a Propensity Score-Matched Ana
Yang Yang, Jie Zhang, Liqun Fang, Xue Jia, Wensheng Zhang
Drug Design, Development and Therapy.2022; Volume 16: 3599. CrossRef - Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study
Andreas Ebbehoj, Kirstine Stochholm, Sarah Forslund Jacobsen, Christian Trolle, Peter Jepsen, Maciej Grzegorz Robaczyk, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Reimar Wernich Thomsen, Esben Søndergaard, Per Løgstrup Poulsen
The Journal of Clinical Endocrinology & Metabolism.2021; 106(5): e2251. CrossRef - Determinants of anxiety and depression among pheochromocytoma patients
Siming Jia, Chengbai Li, Zhuqing Lei, Qiang Xia, Yuqing Jiang
Medicine.2021; 100(3): e24335. CrossRef - Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases
Akiyuki Kawashima, Masakatsu Sone, Nobuya Inagaki, Kentaro Okamoto, Mika Tsuiki, Shoichiro Izawa, Michio Otsuki, Shintaro Okamura, Takamasa Ichijo, Takuyuki Katabami, Yoshiyu Takeda, Takanobu Yoshimoto, Mitsuhide Naruse, Akiyo Tanabe
Endocrine.2021; 74(1): 155. CrossRef - Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan
Endocrinology and Metabolism.2021; 36(2): 322. CrossRef - Clinical Presentation and Perioperative Management of Pheochromocytomas and Paragangliomas: A 4-Decade Experience
Thomas Uslar, Ignacio F San Francisco, Roberto Olmos, Stefano Macchiavelo, Alvaro Zuñiga, Pablo Rojas, Marcelo Garrido, Alvaro Huete, Gonzalo P Mendez, Ignacio Cortinez, José Tomás Zemelman, Joaquín Cifuentes, Fernando Castro, Daniela Olivari, José Miguel
Journal of the Endocrine Society.2021;[Epub] CrossRef - Pheochromocytoma
Zhonghua Liu, Junsheng Ma, Camilo Jimenez, Miao Zhang
American Journal of Surgical Pathology.2021; 45(9): 1155. CrossRef - Perioperative hemodynamic instability in pheochromocytoma and sympathetic paraganglioma patients
Jung Hee Kim, Hyung-Chul Lee, Su-jin Kim, Soo Bin Yoon, Sung Hye Kong, Hyeong Won Yu, Young Jun Chai, June Young Choi, Kyu Eun Lee, Kwang-Woong Lee, Seung-Kee Min, Chan Soo Shin, Kyu Joo Park
Scientific Reports.2021;[Epub] CrossRef - Changes in the Nociception Level Index During Surgical Resection of Paragangliomas: A Case Report
Rita Saynhalath, Umar H. Khan, Gijo Alex, Joseph T. Murphy, Peter Szmuk
A&A Practice.2021; 15(11): e01542. CrossRef - Hypertension Cure and Reducing Pill Burden after Adrenalectomy for Endocrine Hypertension of Adrenal Origin: A Comparative Study from an Asian and UK Cohort
Kee Y Ngiam, Ciaran Durand, Titus C Vasciuc, Chia H Tai, Raluca Orpean, Fiona Eatock, Mehak Mahipal, Tan W Boon
World Journal of Endocrine Surgery.2021; 13(1): 9. CrossRef - A Brief Overview of the Epidemiology of Pheochromocytoma and Paraganglioma in Korea
Yun Mi Choi
Endocrinology and Metabolism.2020; 35(1): 95. CrossRef
- Diabetes
- Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
-
Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
-
Endocrinol Metab. 2019;34(1):80-92. Published online March 21, 2019
-
DOI: https://doi.org/10.3803/EnM.2019.34.1.80
-
-
8,677
View
-
291
Download
-
40
Web of Science
-
43
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes. MethodsMEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized controlled trials (RCTs) of DPP-4 inhibitors from inception to September 2017. We selected eligible RCTs comparing DPP-4 inhibitors with placebo or other antidiabetic agents and reporting at least one renal outcome. A meta-analysis was conducted to calculate standardized mean differences, weighted mean differences (WMDs), relative risks (RRs), and 95% confidence intervals (CIs) for each renal outcome. ResultsWe included 23 RCTs with 19 publications involving 41,359 patients. Overall changes in urine albumin-to-creatinine ratio were comparable between DPP-4 inhibitors and controls (P=0.150). However, DPP-4 inhibitors were associated with significantly lower risk of incident microalbuminuria (RR, 0.89; 95% CI, 0.80 to 0.98; P=0.022) and macroalbuminuria (RR, 0.77; 95% CI, 0.61 to 0.97; P=0.027), as well as higher rates of regression of albuminuria (RR, 1.22; 95% CI, 1.10 to 1.35; P<0.001) compared with controls. Although DPP-4 inhibitors were associated with small but significantly lower estimated glomerular filtration rate (WMD, −1.11 mL/min/1.73 m2; 95% CI, −1.78 to −0.44; P=0.001), there was no difference in the risk of end-stage renal disease between two groups (RR, 0.93; 95% CI, 0.76 to 1.14; P=0.475). ConclusionDPP-4 inhibitors had beneficial renal effects mainly by reducing the risk of development or progression of albuminuria compared with placebo or other antidiabetic agents.
-
Citations
Citations to this article as recorded by - Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
Cardiovascular Diabetology.2024;[Epub] CrossRef - Repurposing DPP-4 Inhibitors as a Novel Intervention in COVID-19: In Silico Analysis for SARS-CoV-2 Spike Glycoprotein Inhibition
Chhanda Charan Danta, Manoj Kumar Mahapatra
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences.2024; 94(3): 635. CrossRef - Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Yong Gong, Xueyan Bai, Donglei Zhang, Xingsheng Yang, Zheng Qin, Yu Yang, Yilun Zhou, Jie Meng, Xin Liu
Lipids in Health and Disease.2024;[Epub] CrossRef - Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
Hideaki Hashimoto, Michihiro Satoh, Shingo Nakayama, Maya Toyama, Takahisa Murakami, Taku Obara, Naoki Nakaya, Takefumi Mori, Atushi Hozawa, Hirohito Metoki
Diabetes, Obesity and Metabolism.2024; 26(10): 4460. CrossRef - Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
Adili Tuersun, Munire Mohetaer, Guanxin Hou, Gang Cheng
Current Therapeutic Research.2024; 101: 100763. CrossRef - Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection
Francisco Epelde
Medicina.2024; 60(11): 1793. CrossRef - Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events
Edoardo Mannucci, Marco Gallo, Andrea Giaccari, Riccardo Candido, Basilio Pintaudi, Giovanni Targher, Matteo Monami
Diabetes, Obesity and Metabolism.2023; 25(2): 444. CrossRef - Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway
Sarah M. AL-Qabbaa, Samaher I. Qaboli, Tahani K. Alshammari, Maha A. Alamin, Haya M. Alrajeh, Lama A. Almuthnabi, Rana R. Alotaibi, Asma S. Alonazi, Anfal F. Bin Dayel, Nawal M. Alrasheed, Nouf M. Alrasheed
International Journal of Molecular Sciences.2023; 24(7): 6532. CrossRef - Take an individualized and multipronged approach when managing older adults with type 2 diabetes
Sheridan M. Hoy
Drugs & Therapy Perspectives.2023; 39(5): 171. CrossRef - Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
Endocrine Practice.2023; 29(7): 509. CrossRef - Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
Cheuk To Chung, Ishan Lakhani, Oscar Hou In Chou, Teddy Tai Loy Lee, Edward Christopher Dee, Kenrick Ng, Wing Tak Wong, Tong Liu, Sharen Lee, Qingpeng Zhang, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou
Cancer Medicine.2023; 12(11): 12299. CrossRef - Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes
Deborah J. Wexler, Ian H. de Boer, Alokananda Ghosh, Naji Younes, Ionut Bebu, Silvio E. Inzucchi, Janet B. McGill, Sunder Mudaliar, David Schade, Michael W. Steffes, William V. Tamborlane, Meng H. Tan, Faramarz Ismail-Beigi, Jill P. Crandall, Melissa Dian
JAMA Internal Medicine.2023; 183(7): 705. CrossRef - SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
M. Ganeva
Trakia Journal of Sciences.2023; 21(1): 54. CrossRef - Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Christian W. Mende
Advances in Therapy.2022; 39(1): 148. CrossRef - Management of Hyperglycemia in Older Adults with Type 2 Diabetes
Gunjan Y. Gandhi, Arshag D. Mooradian
Drugs & Aging.2022; 39(1): 39. CrossRef - Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi, Hao Hu
Expert Review of Pharmacoeconomics & Outcomes Research.2022; 22(4): 555. CrossRef - Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
Hiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, Tomohiro Ueda, Mio Sakuma, Michio Shimabukuro, Osamu Arasaki, Koichi Node, Takashi Nomiyama, Shinichiro Ueda
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 685. CrossRef - Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine.2022; 37(3): 502. CrossRef - The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
Wan-Chia Hsu, Chun-Sheng Lin, Jung-Fu Chen, Chih-Min Chang
Journal of Clinical Medicine.2022; 11(9): 2653. CrossRef - Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Hiroaki Yagyu, Hitoshi Shimano
Journal of Diabetes Investigation.2022; 13(9): 1472. CrossRef - Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure
Ayesha Abdul Qadir Memon, Sarmad Iqbal
Global Journal of Medical, Pharmaceutical, and Biomedical Update.2022; 17: 12. CrossRef - The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
Daniel V. O'Hara, Thomas R. Parkhill, Sunil V. Badve, Min Jun, Meg J. Jardine, Vlado Perkovic
Diabetes, Obesity and Metabolism.2021; 23(3): 763. CrossRef - Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD
Acaris Benetti, Flavia Letícia Martins, Letícia Barros Sene, Maria Heloisa M. Shimizu, Antonio C. Seguro, Weverton M. Luchi, Adriana C. C. Girardi
American Journal of Physiology-Renal Physiology.2021; 320(3): F285. CrossRef - Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
Johannes F.E. Mann, Marcel H.A. Muskiet
Kidney International.2021; 99(2): 314. CrossRef - Renoprotective Effects of DPP-4 Inhibitors
Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, Ryoko Motonaga, Makito Tanabe
Antioxidants.2021; 10(2): 246. CrossRef - Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney
Paul E. Squires, Gareth W. Price, Ulrik Mouritzen, Joe A. Potter, Bethany M. Williams, Claire E. Hills
International Journal of Molecular Sciences.2021; 22(6): 2809. CrossRef - Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Endocrinology and Metabolism.2021; 36(2): 388. CrossRef - Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul, Sin Gon Kim, Natalie Koh, Alice Pik-Shan Kong, Rungroj Krittayaphong, Bernard Kwok, Bien
European Cardiology Review.2021;[Epub] CrossRef - Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
Francesco Prattichizzo, Paola de Candia, Antonio Ceriello
Metabolism.2021; 120: 154799. CrossRef - SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
Robert C. Stanton
Seminars in Nephrology.2021; 41(2): 85. CrossRef - Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Nina Vodošek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs
Pharmaceuticals.2021; 14(6): 561. CrossRef - Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus
Swayam Prakash Srivastava, Han Zhou, Ocean Setia, Alan Dardik, Carlos Fernandez‐Hernando, Julie Goodwin
Journal of the American Heart Association.2021;[Epub] CrossRef - Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Swayam Prakash Srivastava, Rohit Srivastava, Subhash Chand, Julie E. Goodwin
Pharmaceuticals.2021; 14(8): 751. CrossRef - Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: A systematic review and meta-analysis
SaikatK Dalui, Raja Chakraverty, Nafisha Yasmin, Smita Pattanaik, Kaushik Pandit, Suparna Chatterjee
Indian Journal of Endocrinology and Metabolism.2021; 25(4): 283. CrossRef - Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
Yueh-Ting Lee, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li
Frontiers in Pharmacology.2021;[Epub] CrossRef - The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease
Mishal Yousef Alqurashi, Khalid Faisal Alharthi, Abdulaziz Abdulrahman Alshehri, Yazeed Khalid Alharbi, Mohammad Abdulmunem Sanousi, Anas Abdullah Almazyed, Khulud Saeed Alghamdi, Sarah Musaad Alrashidi, Waad Abdullah Qaeed, Amjad Aedh Alasmari
Pharmacophore.2021; 12(3): 91. CrossRef - Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Zoi Kleinaki, Stella Kapnisi, Sofia-Andriani Theodorelou-Charitou, Ilias P. Nikas, Stavroula A. Paschou
Hormones.2020; 19(4): 467. CrossRef - Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy.2020; 11(2): 369. CrossRef - Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai
Cardiovascular Diabetology.2020;[Epub] CrossRef - Novel therapeutic agents for the treatment of diabetic kidney disease
Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
Expert Opinion on Investigational Drugs.2020; 29(11): 1277. CrossRef - Renal protection with glucagon-like peptide-1 receptor agonists
Martina Vitale, Jonida Haxhi, Tiziana Cirrito, Giuseppe Pugliese
Current Opinion in Pharmacology.2020; 54: 91. CrossRef - Loss of Mitochondrial Control Impacts Renal Health
Swayam Prakash Srivastava, Keizo Kanasaki, Julie E. Goodwin
Frontiers in Pharmacology.2020;[Epub] CrossRef - Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Scientific Reports.2019;[Epub] CrossRef
- Miscellaneous
- The Status and Distinct Characteristics of Endocrine Diseases in North Korean Articles Published between 2006 and 2015
-
Kyeong Jin Kim, Shin Ha, Yo Han Lee, Jung Hyun Noh, Sin Gon Kim
-
Endocrinol Metab. 2018;33(2):268-272. Published online June 21, 2018
-
DOI: https://doi.org/10.3803/EnM.2018.33.2.268
-
-
5,461
View
-
48
Download
-
2
Web of Science
-
2
Crossref
-
Abstract
PDFPubReader ePub
- Background
Past decades of division have led to substantial differences in medical environments between South and North Korea. However, little is known about North Korea's medical status and research field, especially regarding endocrinology. In this study, we report the characteristics of North Korea's articles regarding endocrine-related diseases. MethodsAmong the nine medical journals, articles published in Internal Medicine between 2006 and 2015 were reviewed. A total of 2,092 articles were included; among them, 96 articles were associated with endocrinology. We analyzed these articles according to the disease categories they focused on and evaluated their features. ResultsArticles related to diabetes mellitus accounted for 55.2% (n=53) and those to thyroid disease accounted for 28.1% (n=27). Other disease categories, including adrenal gland (n=1), pituitary gland (n=1), and osteoporosis (n=3), comprised minor portions. Regarding diabetes mellitus, more than half the articles (n=33) focused on treatment and complications. Experimental studies were conducted with old hypoglycemic drugs or natural substances for the treatment of hyperglycemia. Regarding thyroid disease, articles related to hyperthyroidism were the most common (51.9%, n=14), followed by thyroid nodule/cancer (18.5%, n=5). Unique article features were short length, no figures, and less than five references. ConclusionNorth Korea's endocrinology articles mainly focused on diabetes mellitus and thyroid disease. Persistent studies have been carried out in North Korea with dedication despite the poor medical environment. We hope that this study will be the beginning of mutual medical exchange and collaboration between North and South Korea.
-
Citations
Citations to this article as recorded by - Surgical Diseases in North Korea: An Overview of North Korean Medical Journals
Sejin Choi, Taehoon Kim, Soyoung Choi, Hee Young Shin
International Journal of Environmental Research and Public Health.2020; 17(24): 9346. CrossRef -
Endocrinology and Metabolism Has Been Indexed in MEDLINE: A Major Achievement
Won-Young Lee
Endocrinology and Metabolism.2019; 34(2): 138. CrossRef
- Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
-
Nam Hoon Kim, Dong-Lim Kim, Kyeong Jin Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
-
Endocrinol Metab. 2017;32(2):241-247. Published online June 23, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.2.241
-
-
5,406
View
-
100
Download
-
25
Web of Science
-
26
Crossref
-
Abstract
PDFPubReader
- Background
Glycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor, vildagliptin, or a thiazolidinedione, pioglitazone, on glycemic variability and oxidative stress in patients with type 2 diabetes. MethodsIn this open label, randomised, active-controlled, pilot trial, individuals who were inadequately controlled with metformin monotherapy were assigned to either vildagliptin (50 mg twice daily, n=17) or pioglitazone (15 mg once daily, n=14) treatment groups for 16 weeks. Glycemic variability was assessed by calculating the mean amplitude of glycemic excursions (MAGE), which was obtained from continuous glucose monitoring. Urinary 8-iso prostaglandin F2α, serum oxidised low density lipoprotein, and high-sensitivity C-reactive protein were used as markers of oxidative stress or inflammation. ResultsBoth vildagliptin and pioglitazone significantly reduced glycated hemoglobin and mean plasma glucose levels during the 16-week treatment. Vildagliptin also significantly reduced the MAGE (from 93.8±38.0 to 70.8±19.2 mg/dL, P=0.046), and mean standard deviation of 24 hours glucose (from 38±17.3 to 27.7±6.9, P=0.026); however, pioglitazone did not, although the magnitude of decline was similar in both groups. Markers of oxidative stress or inflammation including urinary 8-iso prostaglandin F2α did not change after treatment in both groups. ConclusionIn this 16-week treatment trial, vildagliptin, but not pioglitazone, reduced glycemic variability in individuals with type 2 diabetes who was inadequately controlled with metformin monotherapy, although a reduction of oxidative stress markers was not observed.
-
Citations
Citations to this article as recorded by - Vildagliptin Sustained-release and Dapagliflozin Fixed-dose Combination in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review
Subhajyoti Ghosh, Mainak Mukhopadhyay, Mayur Agrawal, Mohammad Shahid, Mahak Lamba, Sudeep Jain, Ashish Prasad, Amit Gupta, Rohan Kesarkar, Sona Warrier, Abhijeet Pednekar
International Journal of Diabetes and Technology.2024; 3(2): 49. CrossRef - Glycemic Variability in Pancreatogenic Diabetes Mellitus: characteristics, Risks, Potential Mechanisms, and Treatment Possibilities
Yuyan Sun, Bing Lu, Yuanwen Hu, Yingqi Lv, Shao Zhong
International Journal of General Medicine.2024; Volume 17: 4297. CrossRef - Clinical implications and pharmacological considerations of glycemic variability in patients with type 2 diabetes mellitus
Alanood A. Howsawi, Manal M. Alem
Scientific Reports.2024;[Epub] CrossRef - What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review
Juan Miguel Huertas Cañas, Maria Alejandra Gomez Gutierrez, Andres Bedoya Ossa
European Endocrinology.2023; 19(2): 4. CrossRef - Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice
Antonio Ceriello, Ali A. Rizvi, Manfredi Rizzo
Advances in Therapy.2022; 39(1): 1. CrossRef - Contrasting Three Non-hypoglycemic Antidiabetic Drug Effects on Glycemic Control in Newly Diagnosed Type II Diabetes Mellitus: An Experimental Study
Abdulhamza Hmood, Mohammed Almasoody, Hameed Hussein Al-Jameel
Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 506. CrossRef - Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis
SuA Oh, Sujata Purja, Hocheol Shin, Minji Kim, Eunyoung Kim
Diabetes and Vascular Disease Research.2022;[Epub] CrossRef - Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Miao Yu
Frontiers in Endocrinology.2022;[Epub] CrossRef - Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
Hae Jin Kim, In Kyung Jeong, Kyu Yeon Hur, Soo-Kyung Kim, Jung Hyun Noh, Sung Wan Chun, Eun Seok Kang, Eun-Jung Rhee, Sung Hee Choi
Diabetes & Metabolism Journal.2022; 46(5): 689. CrossRef - Effect of low dose allopurinol on glycemic control and glycemic variability in patients with type 2 diabetes mellitus: A cross-sectional study
Manal M. Alem
Heliyon.2022; 8(11): e11549. CrossRef - Effect of Hydroxychloroquine on Glycemic Variability in Type 2 Diabetes Patients Uncontrolled on Glimepiride and Metformin Therapy
Rajesh Rajput, Suyasha Saini, Siddhant Rajput, Parankush Upadhyay
Indian Journal of Endocrinology and Metabolism.2022; 26(6): 537. CrossRef - Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon
Diabetes & Metabolism Journal.2021; 45(3): 339. CrossRef - Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications
Bao Sun, Zhiying Luo, Jiecan Zhou
Cardiovascular Diabetology.2021;[Epub] CrossRef - CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review
Anne-Esther Breyton, Stéphanie Lambert-Porcheron, Martine Laville, Sophie Vinoy, Julie-Anne Nazare
Frontiers in Endocrinology.2021;[Epub] CrossRef - Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects
Sahar Hossam Elhini, Amal K. Hussien, Ahmed Abd Elsamie Omran, Asmaa A. Elsayed, Haitham saeed
Clinical and Experimental Pharmacology and Physiology.2021; 48(12): 1589. CrossRef - Vildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress
Fariba Aghahoseini, Alireza Alihemmati, Leila Hosseini, Reza Badalzadeh
Journal of Diabetes & Metabolic Disorders.2020; 19(2): 701. CrossRef - Small changes in glucose variability induced by low and high glycemic index diets are not associated with changes in β-cell function in adults with pre-diabetes
Kristina M. Utzschneider, Tonya N. Johnson, Kara L. Breymeyer, Lisa Bettcher, Daniel Raftery, Katherine M. Newton, Marian L. Neuhouser
Journal of Diabetes and its Complications.2020; 34(8): 107586. CrossRef - Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim
Diabetes, Obesity and Metabolism.2020; 22(2): 173. CrossRef - Glycemic variability: adverse clinical outcomes and how to improve it?
Zheng Zhou, Bao Sun, Shiqiong Huang, Chunsheng Zhu, Meng Bian
Cardiovascular Diabetology.2020;[Epub] CrossRef - Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
Niki Katsiki, Ele Ferrannini
Journal of Diabetes and its Complications.2020; 34(12): 107723. CrossRef - Impact of long-term glucose variability on coronary atherosclerosis progression in patients with type 2 diabetes: a 2.3 year follow-up study
Suhua Li, Xixiang Tang, Yanting Luo, Bingyuan Wu, Zhuoshan Huang, Zexiong Li, Long Peng, Yesheng Ling, Jieming Zhu, Junlin Zhong, Jinlai Liu, Yanming Chen
Cardiovascular Diabetology.2020;[Epub] CrossRef - Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes
Xixiang Tang, Junlin Zhong, Hui Zhang, Yanting Luo, Xing Liu, Long Peng, Yanling Zhang, Xiaoxian Qian, Boxiong Jiang, Jinlai Liu, Suhua Li, Yanming Chen
Cardiovascular Diabetology.2019;[Epub] CrossRef - Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis
Xin Liu, Peng Men, Bo Wang, Gaojun Cai, Zhigang Zhao
Lipids in Health and Disease.2019;[Epub] CrossRef - Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Fahmida Alam, Md. Asiful Islam, Mafauzy Mohamed, Imran Ahmad, Mohammad Amjad Kamal, Richard Donnelly, Iskandar Idris, Siew Hua Gan
Scientific Reports.2019;[Epub] CrossRef - Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis
Subin Lee, Heeyoung Lee, Yoonhye Kim, EunYoung Kim
Scientific Reports.2019;[Epub] CrossRef - Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes
Guillermo E. Umpierrez, Boris P. Kovatchev
The American Journal of the Medical Sciences.2018; 356(6): 518. CrossRef
- Primary Hyperparathyroidism with Extensive Brown Tumors and Multiple Fractures in a 20-Year-Old Woman
-
Ju Hee Choi, Kyoung Jin Kim, Ye Jin Lee, Sun Hwa Kim, Sin Gon Kim, Kwang Yoon Jung, Dong Seop Choi, Nam Hoon Kim
-
Endocrinol Metab. 2015;30(4):614-619. Published online December 31, 2015
-
DOI: https://doi.org/10.3803/EnM.2015.30.4.614
-
-
4,763
View
-
57
Download
-
8
Web of Science
-
7
Crossref
-
Abstract
PDFPubReader
A brown tumor is a benign fibrotic, erosive bony lesion caused by localized, rapid osteoclastic turnover, resulting from hyperparathyroidism. Although brown tumors are one of the most pathognomonic signs of primary hyperparathyroidism, they are rarely seen in clinical practice. In this report, we present a case of 20-year-old woman with recurrent fractures and bone pain. Plain digital radiographs of the affected bones revealed multiple erosive bone tumors, which were finally diagnosed as brown tumors associated with primary hyperparathyroidism due to a parathyroid adenoma. This case shows that multiple, and clinically severe form of brown tumors can even occur in young patients. -
Citations
Citations to this article as recorded by - Osteolytic Lesions (Brown Tumors) of Primary Hyperparathyroidism: A Report of Two Cases
Abrar M Alrotoie, Asia A Aljohani, Renad Alrehaili, Mayar Alharbi, Yousef M Alalawi
Cureus.2024;[Epub] CrossRef - Update on brown tumor of hyperparathyroidism
Alex Guedes, Ricardo Gehrke Becker, Suely Akiko Nakagawa, Aparecida Aguiar Lima Guedes
Revista da Associação Médica Brasileira.2024;[Epub] CrossRef - Diagnostic challenge of the brown tumors in developing country: A case series
Erny Khomariyah, Yunita Purnamasari, Mohammad Hardian Basuki, Stepanus Massora
International Journal of Surgery Case Reports.2024; 123: 110221. CrossRef - Brown tumor of the knee as the first presentation of primary hyperparathyroidism caused by parathyroid adenoma: A case report
Vaishnavi C Tapadia, Romana Riyaz, Abhigan Babu Shrestha, Javeed Akhtar Ankolvi
Radiology Case Reports.2023; 18(5): 1852. CrossRef - Brown tumors in nuclear medicine: a systematic review
Nicolas Jacquet-Francillon, Nathalie Prevot
Annals of Nuclear Medicine.2023; 37(5): 255. CrossRef - Misdiagnosis of brown tumour caused by primary hyperparathyroidism: a case report with literature review
Yanchun Zhong, Yuxi Huang, Jiaquan Luo, Yongjun Ye
BMC Endocrine Disorders.2022;[Epub] CrossRef - Gnathic Bones and Hyperparathyroidism: A Review on the Metabolic Bony Changes Affecting the Mandible and Maxilla in case of Hyperparathyroidism
Hazim Mahmoud Ibrahem
Advances in Medicine.2020; 2020: 1. CrossRef
- Thyroid
- A Rare Manifestation of Hypothyroid Myopathy: Hoffmann's Syndrome
-
Kang Won Lee, Sun Hwa Kim, Kyoung Jin Kim, Sang Hyun Kim, Hee Young Kim, Byung-Jo Kim, Sin Gon Kim, Dong Seop Choi
-
Endocrinol Metab. 2015;30(4):626-630. Published online December 31, 2015
-
DOI: https://doi.org/10.3803/EnM.2015.30.4.626
-
-
7,625
View
-
112
Download
-
9
Web of Science
-
7
Crossref
-
Abstract
PDFPubReader
Hypothyroid myopathy is observed frequently and the resolution of the clinical manifestations of myopathy following thyroid hormone replacement is well known. However, a specific subtype of hypothyroid myopathy, Hoffmann's syndrome, characterized by increased muscular mass (pseudohypertrophy), proximal muscle weakness, muscle stiffness and cramps, is rarely reported. Herein, we describe a 34-year-old male who presented with proximal muscle weakness and non-pitting edema of the lower extremities. He initially visited the neurology department where he was suspected of having polymyositis. Additional laboratory evaluation revealed profound autoimmune hypothyroidism and elevated muscle enzymes including creatine kinase. The patient was started on levothyroxine treatment and, subsequently, clinical symptoms and biochemical parameters resolved with the treatment. The present case highlights that hypothyroidism should be considered in the differential diagnosis of musculoskeletal symptoms even in the absence of overt manifestations of hypothyroidism. To our knowledge, this is the first case reported in Korea. -
Citations
Citations to this article as recorded by - The association of back pain with physical inactivity and hypothyroidism in pregnant women
Chencui Shi, Qiangdong Zou, Hong Wei
Journal of Back and Musculoskeletal Rehabilitation.2024; 37(6): 1663. CrossRef - Hoffmann’s syndrome in the differential work-up of myopathic complaints: a case report
Sabine Winter, Bianka Heiling, Niklas Eckardt, Christof Kloos, Hubertus Axer
Journal of Medical Case Reports.2023;[Epub] CrossRef - Hypothyroidism: A Peculiar Presentation
Rita V Nogueira, Rui Lima, Carina Parente, Pedro Liberal, Lucia Santos
Cureus.2023;[Epub] CrossRef - Hoffman's syndrome as the presenting manifestation of non-primary hypothyroidism in a case of Prader-Willi Syndrome
R. Ghosh, A. Ray, D. Roy, J. Benito-Leon
Neurología.2022; 37(9): 824. CrossRef - Hoffman's syndrome as the presenting manifestation of non-primary hypothyroidism in a case of Prader-Willi Syndrome
R. Ghosh, A. Ray, D. Roy, J. Benito-Leon
Neurología (English Edition).2022; 37(9): 824. CrossRef - Hoffmann’s syndrome necessitating forearm fasciotomy: a case report
Erling Aarsæther, Ragnar Joakimsen, Hanne Halvorsen, Trude Sildnes, Olav Sivertsen, Jan Due
Journal of Medical Case Reports.2020;[Epub] CrossRef - Hypothyroid myopathy: A peculiar clinical presentation of thyroid failure. Review of the literature
Alessandro Sindoni, Carmelo Rodolico, Maria Angela Pappalardo, Simona Portaro, Salvatore Benvenga
Reviews in Endocrine and Metabolic Disorders.2016; 17(4): 499. CrossRef
- Thyroid
- Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease
-
Sun Hwa Kim, Hee Young Kim, Kwang Yoon Jung, Dong Seop Choi, Sin Gon Kim
-
Endocrinol Metab. 2013;28(1):61-64. Published online March 25, 2013
-
DOI: https://doi.org/10.3803/EnM.2013.28.1.61
-
-
4,609
View
-
32
Download
-
4
Crossref
-
Abstract
PDFPubReader
Radioactive iodine (RAI) therapy has been used as a treatment option for Graves' disease, and it has been widely accepted to be safe. On the other hand, some evidence suggests that RAI therapy is possibly associated with a small increased risk of thyroid cancer. Herein, we report a rare case of anaplastic thyroid carcinoma (ATC) associated with Graves' disease, following RAI treatment. A 42-year-old woman had been diagnosed with Graves' disease and although she was treated with an antithyroid drug, she remained in a hyperthyroid state, which led to two RAI treatments. More than 10 years later, the patient revisited our clinic due to hoarseness, dysphagia, and dyspnea, which had lasted for 2 months. Neck computed tomography suggested thyroid carcinoma and a lymph node biopsy showed metastatic papillary carcinoma. The patient underwent total thyroidectomy and was finally diagnosed as having an ATC. It is not clear if the occurrence of ATC reported here was influenced by the RAI therapy or alternatively, it may only represent the delayed recognition of a rare change in the natural history of Graves' disease. Nevertheless, this report is worthwhile since it presents a very rare case of ATC that occurred eleven years after the RAI therapy for Graves' disease. -
Citations
Citations to this article as recorded by - V600E BRAF-mutated anaplastic thyroid carcinoma after radioactive iodine for Graves’ disease: a case report and a review of the literature
Marta Villanova, Luigi di Filippo, Filippo Maria Bolamperti, Carlo Rodella, Laura Castellino, Raffaele Giubbini
Clinical and Translational Imaging.2024; 12(5): 467. CrossRef - Evaluation of ultrasonographical and cytological features of thyroid nodules in patients treated with radioactive iodine for hyperthyroidism
Muhammet C. Bilginer, Didem Ozdemir, Fatma N. C. Seyrek, Nilufer Yildirim, Aylin K. Yazgan, Mehmet Kilic, Reyhan Ersoy, Bekir Cakir
Diagnostic Cytopathology.2020; 48(1): 3. CrossRef - Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves’ disease by radioactive iodine
O Hamdy, S Raafat, GA Saleh, K Atallah, Mahmoud M Saleh, AM Shebl, MA Hegazy
The Annals of The Royal College of Surgeons of England.2019; 101(5): e122. CrossRef - Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef
- A Case of Multiple Osteoporotic Compression Fractures in Young Man with Budd-Chiari Syndrome.
-
Sun Hwa Kim, Tae Un Yang, Byeong Kwang Choi, Hye Jin Yoo, Ji A Seo, Kyung Mook Choi, Nan Hee Kim, Sin Gon Kim, Sei Hyun Baik, Dong Seop Choi, Hae Yoon Choi
-
Endocrinol Metab. 2012;27(4):334-339. Published online December 20, 2012
-
DOI: https://doi.org/10.3803/EnM.2012.27.4.334
-
-
Abstract
PDF
- Osteoporosis in young men is extremely rare. In this report, we demonstrate a rare case of multiple vertebral fractures discovered in a young man with Budd-Chiari syndrome without prior history of trauma. A 29-year-old man was diagnosed as Budd-Chiari syndrome 12 years ago and underwent a mesocaval shunt to relieve the hepatic vein obstruction and was on warfarin therapy. He suffered from low back pain and it was not relieved by analgesics. A T-L spine X-ray revealed multiple compression fractures and the z-score at lumbar spine was -3.7 which is below the expected range for that age. The patient was treated with calcium, vitamin D and bisphosphonate, and showed clinical improvement. This case highlights the importance of the investigation for secondary osteoporosis in young adults with an underlying disease that alters bone metabolism.
- Thyroid Dysfunction of North Korean Women Living in South Korea, Focusing on Subclinical Hypothyroidism.
-
Joo Hyung Kim, Sol Ah Park, Nam Hoon Kim, Jae Hee Ahn, Yoon Jung Kim, Myongjin Cho, Yoon Jung Lee, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sin Gon Kim
-
Endocrinol Metab. 2012;27(3):200-207. Published online September 19, 2012
-
DOI: https://doi.org/10.3803/EnM.2012.27.3.200
-
-
3,847
View
-
29
Download
-
2
Crossref
-
Abstract
PDF
- BACKGROUND
Thyroid function depends on ethnic and environmental factors. North Korean refugees have the same genetic background as South Koreans, but they have been exposed to different environments. This study examines the prevalence and pattern of thyroid disorders in North Korean women living in South Korea, focusing on subclinical hypothyroidism (SCH). METHODS: The intended sample was a total of 327 North Korean women residing in Seoul. Health questionnaires and medical examinations, including serum thyrotropin (thyroid stimulating hormone, TSH), free thyroxine, and thyroid autoantibodies, were conducted. RESULTS: The prevalence of SCH was 9.4%. In logistic regression analysis, smoking, menopause, length of stay in South Korea, body mass index, history of thyroid disease, and metabolic syndrome were not associated with the risk of SCH. Whereas, the positivity of autoantibodies were associated with a high risk for SCH (odds ratio [OR], 4.840; 95% confidence interval [CI], 1.80-13.017; P = 0.002), and age was associated with a low risk for SCH (OR, 0.94; 95% CI, 0.888-0.994; P = 0.031). The serum TSH levels also decreased with increasing age, and in particular, there was significant difference between 30-39 years, and over 60 years (2.33 +/- 1.51 microIU/mL vs. 1.54 +/- 0.73 microIU/mL, P = 0.028). CONCLUSION: In North Korean women, the positivity of autoantibodies was associated with a high risk for SCH. But interestingly, a younger age was associated with a high risk for SCH. Considering that they suffered from severe famine at the period of growth, and this led to malnutrition, their thyroid dysfunction might be associated with the peculiar environment that they experienced.
-
Citations
Citations to this article as recorded by - Systematic review of evidence on public health in the Democratic People’s Republic of Korea
John J Park, Ah-Young Lim, Hyung-Soon Ahn, Andrew I Kim, Soyoung Choi, David HW Oh, Owen Lee-Park, Sharon Y Kim, Sun Jae Jung, Jesse B Bump, Rifat Atun, Hee Young Shin, Kee B Park
BMJ Global Health.2019; 4(2): e001133. CrossRef - Environmental Factors and Thyroid Dysfunction
Hyun-Kyung Chung
Endocrinology and Metabolism.2012; 27(3): 191. CrossRef
- Hyperprolactinemia-Associated Breast Uptake of Radioiodine Following 131I Postablation Scan in Differentiated Thyroid Cancer.
-
Jae Hee Ahn, Sun Young Kim, Ye Ji Kim, Suk Young Lee, Jae Hyoung Lee, Seung Hun Kang, Ho Cheol Hong, Sae Jeong Yang, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Hae Yoon Choi
-
Endocrinol Metab. 2011;26(4):345-347. Published online December 1, 2011
-
DOI: https://doi.org/10.3803/EnM.2011.26.4.345
-
-
2,266
View
-
22
Download
-
1
Crossref
-
Abstract
PDF
- Scanning with whole-body 131I scintigraphy after surgery has been a valuable diagnostic modality in the surveillance of patients with differentiated thyroid cancer. Radioiodine uptake is rarely observed in non-lactating breast tissue, which mimics thyroid cancer metastasis. We now report a case of a 45-year-old female thyroid cancer patient who underwent radioiodine therapy, and in whom breast uptake of radioiodine was observed on a post-therapy whole body scan. Her serum prolactin level was elevated to 328 ng/mL at the time of the radioiodine uptake, and the hyperprolactinemia was induced by her antipsychotic medications. Six months after she discontinued that medication, her serum prolactin level was normalized to 12.6 ng/mL and breast uptake of iodine was no longer present in a follow-up whole body scan.
-
Citations
Citations to this article as recorded by - Incidental Findings of Intense Radioiodine Uptake in Struma Ovarii and Bilateral Nonlactating Breasts Simultaneously on Postablation 131I SPECT/CT for Papillary Thyroid Cancer
Hye-kyung Shim, Mi Ra Kim
Nuclear Medicine and Molecular Imaging.2016; 50(4): 353. CrossRef
- Successful Localization of Distant Metastasis in Parathyroid Carcinoma Using Intraoperative Parathyroid Hormone Assay.
-
Ho Cheol Hong, Sun Won Kim, Tae Hyung Kim, In Hye Cha, Jae Hee Ahn, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Hyun Koo Kim, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Jae Bok Lee, Sei Hyun Baik, Dong Seop Choi
-
Endocrinol Metab. 2011;26(1):92-96. Published online March 1, 2011
-
DOI: https://doi.org/10.3803/EnM.2011.26.1.92
-
-
2,315
View
-
24
Download
-
1
Crossref
-
Abstract
PDF
- Intra-operative parathyroid hormone (IOPTH) assay is a useful tool to confirm complete excision of all hyper-functioning parathyroid gland tissue. In this report, we describe a case with successful localization of distant metastasis in a patient with parathyroid carcinoma using the IOPTH assay. A 53-year-old man presented to our clinic with a serum calcium level of 11.8 mg/dL and an intact PTH level of 233.3 pg/mL. He had been treated for parathyroid carcinoma eleven years ago. Two suspected metastatic lesions were detected on the chest computed tomography. Due to the vastly different surgical field necessary to excise each lesion, we preferentially removed only one lesion and we monitored the other remaining suspected lesion without resection via IOPTH assay. Six months later, the patient's serum calcium and intact PTH levels remained within their normal ranges. To the best of our knowledge, this is the first case to effectively utilize IOPTH assay for the management of metastatic parathyroid carcinoma.
-
Citations
Citations to this article as recorded by - The association of abdominal obesity, obesity and parathyroid hormone in Korean adults (aged≥50 years): The Korea National Health and Nutrition Survey, 2011
Kyu Su Lee, Yo Sang Yoon, Hyun Yoon
Journal of the Korea Academia-Industrial cooperation Society.2015; 16(6): 3882. CrossRef
- Ectopic ACTH Syndrome with Bilateral Pheochromocytoma in Multiple Endocrine Neoplasia Type 2A.
-
Ji Mi Moon, Yoon Jung Kim, Young Jin Seo, Hye Yoon Choi, Joo Hyong Kim, Ju Ri Park, Yun Jeong Lee, Hee Young Kim, Sin Gon Kim, Dong Seop Choi
-
J Korean Endocr Soc. 2009;24(4):265-271. Published online December 1, 2009
-
DOI: https://doi.org/10.3803/jkes.2009.24.4.265
-
-
2,457
View
-
34
Download
-
4
Crossref
-
Abstract
PDF
- Multiple endocrine neoplasia type 2A (MEN 2A) is an autosomal dominant syndrome characterized by the presence of medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism. MEN 2A arises due to a germline missense mutation of the RET proto-oncogene. Specific RET mutation analysis has revolutionized the diagnosis and therapy of this disorder, and early thyroidectomy may have lowered the morbidity and mortality associated with these diseases. Ectopic adrenocorticotropic hormone (ACTH) syndrome is characterized by hypercortisolism due to the hypersecretion of ACTH outside of the pituitary gland; the most common causes are malignancies, but rarely adrenal pheochromocytoma may be the cause.
-
Citations
Citations to this article as recorded by - Pheochromocytoma With High Adrenocorticotropic Hormone Production Capacity Without Pigmentation and Cushingoid Symptoms: A Case Report With a Literature Review
Gen Mizutani, Masashi Isshiki, Eisuke Shimizu, Daigo Saito, Akira Shimada
Cureus.2024;[Epub] CrossRef - Ectopic ACTH- and/or CRH-Producing Pheochromocytomas
Patrick F Elliott, Thomas Berhane, Oskar Ragnarsson, Henrik Falhammar
The Journal of Clinical Endocrinology & Metabolism.2021; 106(2): 598. CrossRef - Severe Cushing Syndrome Due to an ACTH-Producing Pheochromocytoma: A Case Presentation and Review of the Literature
Jenan N Gabi, Maali M Milhem, Yara E Tovar, Emhemmid S Karem, Alaa Y Gabi, Rodhan A Khthir
Journal of the Endocrine Society.2018; 2(7): 621. CrossRef - Adrenocorticotropic hormone (ACTH)-producing pheochromocytoma presented as Cushing syndrome and complicated by invasive aspergillosis
Jae Ho Cho, Da Eun Jeong, Jae Young Lee, Jong Geol Jang, Jun Sung Moon, Mi Jin Kim, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
Yeungnam University Journal of Medicine.2015; 32(2): 132. CrossRef
- A Case of Recurrent Ectopic Parathyroid Adenoma Developed 22 Years after the Initial Parathyroidectomy.
-
Yoon Jung Kim, Ji A Seo, Ji Mi Moon, Young Jin Seo, Hae Yoon Choi, Hye Sook Kim, Sin Gon Kim, Kyeung mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
-
J Korean Endocr Soc. 2009;24(4):260-264. Published online December 1, 2009
-
DOI: https://doi.org/10.3803/jkes.2009.24.4.260
-
-
Abstract
PDF
- Persistent or recurrent primary hyperparathyroidism after initial parathyroid surgery occurs at rates of 1.5~10%. A single missed parathyroid adenoma accounts for the majority of persistent hyperparathyroidism, whereas metachronous parathyroid adenoma is a rare cause of recurrent hypercalcemia. We report a case of a 39-year-old female who presented with recurrent pancreatitis. She had symptoms of hyperparathyroidism such as hypercalcemia, hypophosphatemia, hypercalciuria, nephrocalcinosis, and osteoporosis. She had a 2-cm firm neck mass under the right submandibular area. She was diagnosed with primary hyperparathyroidism 22 years ago. At that time, the right upper and lower parathyroid glands were removed after exploration of all parathyroid glands, and a right upper parathyroid adenoma was diagnosed. Now, she had a second surgery to remove the right submandibular mass with intraoperative PTH monitoring, which was diagnosed as a parathyroid adenoma in an ectopic supernumerary parathyroid gland. Because of hungry bone syndrome, she received calcium carbonate replacement therapy and has no evidence of recurrence. Here, we report a recurrent parathyroid adenoma in the undescended, supernumerary parathyroid gland after a long interval from the initial surgery.
- A Case of Fulminant Type 1 Diabetes Mellitus Complicated with Ischemic Ileitis.
-
Se Won Oh, Ju Ri Park, Yun Jeong Lee, Hee Yeong Kim, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sin Gon Kim
-
J Korean Endocr Soc. 2009;24(2):116-120. Published online June 1, 2009
-
DOI: https://doi.org/10.3803/jkes.2009.24.2.116
-
-
Abstract
PDF
- Fulminant type 1 diabetes is characterized by diabetes with an abrupt onset, severe metabolic acidosis at diagnosis, a low HbA1c level and negativity for islet cell-related autoantibodies, and this illness has been classified as type 1B diabetes by the WHO. The prevalence of this disease is higher in Japan than any other country and recently, there have been an increasing number of such case reports in Korea. Genetic factors and environmental factors such as virus infection and an immune mechanism have been suggested as the mechanism of the pathophysiology, but this remains to be clarified.
- Normal Repetitive Pregnancies and Tumor Regression Induced by Low-Dose Bromocriptine in a Patient with Macroprolactinoma.
-
Hye Jung Choi, Jin Yong Park, Woo Seok Choi, Jong Gyu Song, Hee Young Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
-
J Korean Endocr Soc. 2009;24(1):42-46. Published online March 1, 2009
-
DOI: https://doi.org/10.3803/jkes.2009.24.1.42
-
-
Abstract
PDF
- Prolactin-secreting adenomas are the most common pituitary tumors. Menstrual disturbances and infertility are the main complaints in women with prolactinoma. Dopaminergic agonists such as bromocriptine are well-established treatments for prolactinoma when pregnancy is desired. Pregnancy-related outcomes in macroprolactinoma are worse than those in microprolactinoma. In addition, symptomatic tumor expansion during pregnancy occurs in 30% of women with macroprolactinoma. Therefore, when women with macroprolactinoma are planning a pregnancy, serum prolactin level should be normalized and the tumor volume significantly reduced. On the other hand, a spontaneous regression of macroprolactinoma can occur after pregnancy. We report a case of macroprolactinoma showing significant tumor regression during repeated pregnancies and low dose bromocriptine treatment, with a literature review.
- A Case of Graves' Disease with Pheochromocytoma.
-
Hye Sook Kim, Hyung Joon Joo, Yoon Seok Choi, Eun Sun Kim, Soo Yeon Park, Yun Jeong Lee, Hee Young Kim, Ji A Seo, Sin Gon Kim, Dong Seop Choi
-
J Korean Endocr Soc. 2007;22(6):465-469. Published online December 1, 2007
-
DOI: https://doi.org/10.3803/jkes.2007.22.6.465
-
-
2,179
View
-
25
Download
-
1
Crossref
-
Abstract
PDF
- Graves' disease is an autoimmune disorder in which thyrotropin-stimulating hormone receptor antibodies stimulate the thyroid gland. Stress hormones such as catecholamine are known to play important roles in the pathogenesis of Graves' disease. Pheochromocytoma with Graves' disease is extremely rare, and no case has been reported within the Republic of Korea. However, according to previous studies conducted abroad, pheochromocytoma influences the pathogenesis of Graves' disease by producing excessive cathecholamine. In the present report, we describe a 65-year-old female patient with paroxysmal hypertension and rapidly progressive body weight loss who was diagnosed as having Graves'disease with pheochromocytoma.
-
Citations
Citations to this article as recorded by - Graves' Disease Accompanied by Pheochromocytoma: Report of a Case
Jin-Hwa Kim, Sang-Jun Lee, Ji-Hye Shin, Mi-Ra You, Jae-Sik Jung, Sang-Yong Kim, Hak-Yeon Bae
Journal of Korean Endocrine Society.2009; 24(2): 126. CrossRef
- The Evaluation and Follow-up of Adrenal Incidentaloma.
-
Sin Gon Kim, Dong Seop Choi
-
J Korean Endocr Soc. 2007;22(4):257-259. Published online August 1, 2007
-
DOI: https://doi.org/10.3803/jkes.2007.22.4.257
-
-
2,017
View
-
18
Download
-
1
Crossref
-
Abstract
PDF
- No abstract available.
-
Citations
Citations to this article as recorded by - Characterization of Incidentally Detected Adrenal Pheochromocytoma
Soon Jib Yoo, Woohyeon Kim
Endocrinology and Metabolism.2012; 27(2): 116. CrossRef
- Two Cases of Acromegaly with Empty Sella Syndrome Treated by Long-Acting Release Octreotide.
-
Dong Jin Kim, Young Jin Seo, Nam Hoon Kim, Hye Soo Chung, Chai Ryoung Eun, Hye Jung Choi, Hye Sook Kim, Sae Jeong Yang, Juri Park, Hye Jin Yoo, Soo Yeon Park, Yun Jeong Lee, Ohk Hyun Ryu, Kye Won Lee, Hee Young Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
-
J Korean Endocr Soc. 2007;22(2):135-141. Published online April 1, 2007
-
DOI: https://doi.org/10.3803/jkes.2007.22.2.135
-
-
Abstract
PDF
- Two cases of typical acromegaly with empty sella syndrome presented to our institution. In the natural course of untreated pituitary adenoma, empty sella syndrome may result from necrosis by infarction or from hemorrhage of the pituitary gland. In our patients, the secretion of growth hormone continued in spite of the existence of empty sella syndrome. In one case, we confirmed the hypersecretion of growth hormone from sella by jugular vein sampling. Medical therapy with somatostatin analogue was attempted because there was no obvious mass in the sella. After 6~12 months of treatment with long-acting release octreotide, clinical features in our patients were improved, and the level of growth hormone and IGF-1 were also normalized.
- Comparison of Target Organ Damages between Primary Aldosteronism and Essential Hypertension.
-
Juri Park, Dong Jin Kim, Sae Jeong Yang, Sook Hae Kim, Soo Yeon Park, Hye Jin Yoo, Yun Jeong Lee, Hee Young Kim, Ohk Hyun Ryu, Kye Won Lee, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
-
J Korean Endocr Soc. 2007;22(1):11-18. Published online February 1, 2007
-
DOI: https://doi.org/10.3803/jkes.2007.22.1.11
-
-
2,434
View
-
21
Download
-
3
Crossref
-
Abstract
PDF
- BACKGROUND
A number of recent clinical studies have reported marked target organ damages in patients with primary aldosteronism. The aim of this study was to compare the incidence of target organ damages in patients with primary aldosteronism (PA) and essential hypertension (EHT). METHODS: The clinical records of 41 PA patients, over a 20-year period, were retrospectively analyzed. The clinical characteristics and incidence of target organ damages of 33 of the patients in this group were compared with those of 66 patients with essential hypertension, directly matched for age, gender and mean blood pressure. 8 of the PA patients could not be matched with EHT patients for age, gender and mean blood pressure, so were excluded from the comparison. The patients with essential hypertension were sampled from patients who visited for the evaluation of hypertension. RESULTS: Ischemic heart diseases were found in 18.2 and 10.6% of patients with PA and EHT, respectively (P = 0.22). From echocardiograms, left ventricular hypertrophy was found in 93.3% and 61.4% of patients with PA and EHT, respectively (P = 0.017). The degrees of left ventricular hypertrophy were correlated with the levels of serum aldosterone, with an r value of 0.490 (P < 0.005). Cerebrovascular attack was found in 18.2% and 1.5% of patients with PA and EHT, respectively (P = 0.005). Hypertensive retinopathy was found in 50% and 33.3% of patients with PA and EHT (P = 0.255), and nephropathy was found in 42.4% and 25.8% of patients with PA and EHT, respectively (P = 0.074). CONCLUSION: Patients with primary aldosteronism had target organ damages more frequently than with those with essential hypertension, which was independent of blood pressure.
-
Citations
Citations to this article as recorded by - Changes in the clinical manifestations of primary aldosteronism
Sun Hwa Kim, Jae Hee Ahn, Ho Cheol Hong, Hae Yoon Choi, Yoon Jung Kim, Nam Hoon Kim, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Nan Hee Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
The Korean Journal of Internal Medicine.2014; 29(2): 217. CrossRef - Comparing the Prevalence of Primary Aldosteronism in Hypertensive Diabetic and Non-diabetic Patients
Yi Sun Jang, Koon Soon Kim, Hye Soo Kim
Journal of Korean Endocrine Society.2009; 24(4): 254. CrossRef - Aldosterone as a Cardiovascular Risk Factor
Soon Jib Yoo
Journal of Korean Endocrine Society.2007; 22(1): 8. CrossRef
- A Case of Sheehan's Syndrome Presenting Central Diabetes Insipidus.
-
Dong Jin Kim, Nan Hee Kim, Ju Ri Park, Sae Jeong Yang, Hye Suk Kim, Hye Jin Yoo, Soo Yeon Park, Ohk Hyun Ryu, Kye Won Lee, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
-
J Korean Endocr Soc. 2006;21(4):333-337. Published online August 1, 2006
-
DOI: https://doi.org/10.3803/jkes.2006.21.4.333
-
-
Abstract
PDF
- Sheehan's syndrome occurs as a result of ischemic pituitary necrosis due to severe postpartum hemorrhage. The manifestations of this clinical syndrome are most often caused by a deficiency in the hormones produced by the anterior pituitary gland, whereas the neurohypophysis is usually preserved but can be involved in severe cases that manifest as diabetes insipidus. This is a report of Sheehan's syndrome that manifested with diabetes insipidus as presenting symptom 2 month's after delivery. The patient suffered massive bleeding, so received a blood transfusion. A combined pituitary stimulation and water deprivation test revealed deficiencies of not only anterior pituitary hormones, such as growth hormone and prolactin, but also of anti-diuretic hormone. We report this case, with a review of the literature.
- A Case of Primary Hyperparathyroidism Caused by Cystic Parathyroid Adenoma, Diagnosed during Intra-Operative PTH Monitoring.
-
Hye Jin Yoo, Nan Hee Kim, Soo Yeon Park, Dong Jin Kim, Sae Jeung Yang, Ju Ri Park, Hee Young Kim, Ji A Seo, Kye Won Lee, Sin Gon Kim, Kyung Mook Choi, Jae Bok Lee, Young Seok Lee, Sei Hyun Baik, Dong Seop Choi
-
J Korean Endocr Soc. 2005;20(3):278-282. Published online June 1, 2005
-
DOI: https://doi.org/10.3803/jkes.2005.20.3.278
-
-
Abstract
PDF
- Primary hyperparathyroidism is the most frequent cause of hypercalcemia, and its prevalence is increasing due to the routine examination of serum calcium levels. Primary hyperparathyroidims is most commonly caused by an adenoma or hyperplasia of the parathyroid gland. A cystic parathyroid adenoma is an extremely rare cause of primary hyperparathyroidism. In our case, a-79-year old female presented with lower back pain and constipation. Her serum calcium, phosphate and immunoreactive parathyroid homone levels were 15.6, 1.8mg/dL and 371.8pg/mL, respectively. Neck CT revealed a cystic mass and a contour bulging heterogeneous mass in the left inferior right thyroid gland, respectively. These mass lesions were removed, and the intra-operative parathyroid hormone levels monitored, to confirm the complete resection. After removing the left cystic mass to the inferior thyroid, the serum calcium and immunoreactive parathyroid hormone levels quickly returned to normal. We report a case of primary hyperparathyroidism, caused by a cystic parathyroid adenoma, with a brief review of the literature
- A Case of Congenital Adrenal Hyperplasia due to 11beta-Hydroxylase Deficiency.
-
Ohk Hyun Ryu, Hye Jin Yoo, Soo Yeon Park, Soon Beom Kwon, Sang Soo Park, Hee Young Kim, Kye Won Lee, Ji A Seo, Jeong Heon Oh, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
-
J Korean Endocr Soc. 2004;19(1):58-63. Published online February 1, 2004
-
-
-
Abstract
PDF
- Congenital adrenal hyperplasia refers to a group of autosomal recessive disorders that is defective in the synthesis of cortisol. The enzymes most often affected are 21-hydroxylase and 11beta hydroxylase. The low levels of cortisol stimulate the pituitary gland to release ACTH. Chronic elevation of the ACTH level causes bilateral adrenal hyperplasia and a secondary increase in androgen formation. We examined a 19 year-old woman presented with clitoral hypertrophy and vaginal spotting. The subjects basal level of serum cortisol was low, but the serum levels of ACTH, 17a-hydroxyprogesterone, deoxy-corticosterone were elevated. The urinary excretions of 17-ketosteroids and 17-hydroxycorticosteroids were also increased. The karyotyping study and transrectal ultrasonography showed normal findings. The patient underwent clitoris reduction surgery and received hydrocortisone. To the best of our knowledge, this is the first case of 11beta-Hydroxylase deficiency in Korea.
- A Case of Multiple Endocrine Neoplasia 2A with Germ Line Mutation of RET Gene.
-
Hee Young Kim, Ji Yeon Lee, Sung Bum Kim, Kye Won Lee, Ji A Seo, Jeong Heon Oh, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
-
J Korean Endocr Soc. 2003;18(5):481-488. Published online October 1, 2003
-
-
-
Abstract
PDF
- Multiple endocrine neoplasia 2A (MEN 2A) is an autosomal dominantly inherited disease, composed of medullary thyroid carcinoma, pheochromocytoma and hyperparathyroidism. The activation of germ-line mutations in the RET proto-oncogene are responsible for MEN 2. The analysis of the RET mutations has replaced the measurement of the calcitonin level in the diagnosis of the MEN carrier state. Specific RET codon mutations correlate with the MEN 2 syndromic variant, the age at onset of the medullary thyroid carcinoma (MTC) and the aggressiveness of the MTC. Herein, our experience of a 47-year-old woman, who had a bilateral pheochromocytoma and MTC, and MEN 2A confirmed by the detection of an RET proto-oncogene mutation at axon 10 on codon 618, is reported. Her sister was found to have the same mutant gene. After a total thyroidectomy and bilateral adrenalectomy, the calcitonin and catecholamine levels were normalized, and the patient discharged without problems. This case is reported, with a review of the literature.
- Clinical Study of the Pheochromocytoma.
-
Dong Hyun Shin, Sin Gon Kim, Dong Rim Kim, Nan Hee Kim, Kyung Mook Choi, Saih Yun Baik, Dong Seop Choi, Sung Ock Suh
-
J Korean Endocr Soc. 2002;17(4):554-563. Published online August 1, 2002
-
-
-
Abstract
PDF
- BACKGROUND
Pheochromocytoma may arise within the adrenal medulla, or in other locations where sympathetic ganglia or chromaffin tissues are known to exist. Approximately 0.1% of hypertensive patients have pheochromocytoma. Most of this hypertension can be cured by surgical removal of the tumor, but lethal complication can develop if proper treatment is not prepared. Therefore, accurate diagnosis and preoperative preparation is very important. The objective of this study was to evaluate the clinical characteristics of pheochromocytoma and the blood pressure change following tumor removal. METHOD: The medical records of 45 patients [29 cases of intra-adrenal, 16 cases of extra-adrenal (paraganglioma)] diagnosed with of pheochromocytoma at Korea University Medical Center between 1991 and 2001 were reviewed. RESULTS: Twenty of the cases were male and 25 were female. The mean age of these patients was 43 years old. Hypertension, headaches, palpitations and impaired glucose tolerance were observed more frequently in cases of intra-adrenal tumor than in those of extra-adrenal. In the extra-adrenal group, abdominal pain, hypertension and nausea were more frequently observed. A biochemical study showed that the sensitivity of the test for catecholamines and metabolites in 24 hours urine was over 80%. For the localization of tumors we used abdominal CT and MIBG. The sensitivities of the CT and MIBG for the tumor localization were 97 and 91%, respectively. Blood pressures during the operations were effectively controlled by preoperative treatment with phenoxybenzamine (non-competitive, non-selective -adrenoreceptor antagonists). CONCLUSION: Surgical treatment cured 23 of the 30 cases of hypertension with pheochromocytoma. We have to take careful approaches in the care of the patient who may have pheochromocytoma, due to the various clinical signs and symptoms.
- A Case of Malignant Pleural Effusion with Pleural Metastasis in a Patient with Papillary Thyroid Carcinoma.
-
Ju Young Kim, Dae Won Park, Jin O Na, Byoung Yeon Hwang, Dong Lim Kim, Dong Hyun Shin, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sung Jin Cho, Nan Hee Kim
-
J Korean Endocr Soc. 2002;17(2):269-274. Published online April 1, 2002
-
-
-
Abstract
PDF
- Papillary thyroid carcinomas comprise approximately 80 percent of all thyroid cancers, but haves a good prognosis, with overall survival rates at 10 years of about 80 to 95 percent. They spreads through the lymphatic system, and the lung is the most frequent metastasis site. If distant metastasis is present, the overall survival rate is about 40 percent. Although malignant pleural effusion, with pleural metastasis is a rare complication in patients with papillary thyroid carcinoma, the development of malignant pleural effusion is an extremely adverse prognostic indicator. We recently experienced a case of malignant pleural effusion with papillary thyroid carcinoma. A 54-year-old woman was admitted to the hospital because of dyspnea. A chest X-ray showed massive pleural effusion in the right hemithorax. Previously total thyroidectomy, and iodine-131 therapy had been performed, but a local recurrence and pulmonary metastasis developed 5 years later, accompanied by malignant pleural effusion with pleural metastasis. We performed diagnostic thoracentesis, which confirmed a metastatic papillary thyroid carcinoma. This patient was a rare case of paplillary thyroid carcinoma, in which the disease was represented by a rapid deterioration with malignant pleural effusion. So we report this case with a review of the literature.
- The Association between CRP and the Metabolic Syndrome in Korean Adults.
-
Sin Gon Kim, Dong Lim Kim, Dong Hyun Shin, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
-
J Korean Endocr Soc. 2002;17(2):226-235. Published online April 1, 2002
-
-
-
Abstract
PDF
- BACKGROUND
Metabolic syndrome (MS) is characterized by insulin resistance accompanied by one or more of the following: obesity, hypertension, impaired glucose tolerance, low HDL cholesterol levels, and/or hypertriglyceridemia. However, the precise underlying pathogenic mechanism of MS is not known. Several recent reports have suggested a positive association between components of MS and markers of the acute-phase response, including C-reactive protein (CRP). These results imply that MS is accompanied by an ongoing inflammatory process. The purpose of our study was to evaluate the association between circulating levels of C-reactive protein, a sensitive systemic marker of inflammation, with components of metabolic syndrome in Korean adults. METHODS: A total of 1,461 subjects aged between 20 and 81 years, who visited the Health Management Center at Korea university between November 2000 and February 2001 were studied. We investigated the correlation between CRP levels and components of MS. The components of MS were categorized, and age-sex adjusted mean values of CRP calculated for the categorized components. The BMI was categorized into 5 classes, and the CRP levels examined according to their BMI class. In addition, subjects with a different number of the MS components were grouped as follows: group 1 for 0 components, group 2 for 1 components, group 3 for 2 components and group 4 for > or = 3 components, and the CRP levels calculated for each group. RESULTS: There were significant positive correlations of CRP levels with age, BMI, TG, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBS), uric acid, insulin,and homeostasis model assessment IR (HOMAIR). A significant inverse correlation was observed between CRP levels and serum HDL. From the multivariate analysis, age and BMI were significantly correlated with CRP levels. The means of the CRP for the categorized components of MS were significantly higher in the BMI categories: > or =25 for female/27 for male, TG > or =200 mg/dL, fasting plasma glucose > or =126 mg/dL and blood pressure > or =140/90 mmHg, and the CRP levels by BMI class were: 1.19 (BMI <18.5), 1.54 (BMI 18.5~22.9), 1.59 (BMI 23.0~24.9), 1.77 (BMI 25.0~29.9) and 2.07 (BMI >30.0) mg/L. Furthermore, the increase in the CRP levels in relation to the numbers of MS were 1.46 (group 1), 1.70 (group 2), 1.95 (group 3) and 2.11 mg/L (group 4) with statistical significance. CONCLUSION: The above data showed associations between the CRP levels and the different components of MS. This might suggest that MS in Koreans could be accompanied by a systemic inflammation response
|
KES
